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ABSTRACT 
GAL ANTIGEN AND RUTINOSE GLYCOSIDES AS MODEL 
COMPOUNDS FOR THE DESIGN OF CLASSICAL AND 
CONFORMATIONAL GLYCOMIMETICS   
                                                                                                                    Dhwani Mehta 
αGal or Galili epitope (αGal(1→3)βGal(1→4)GlcNAc) is a natural trisaccharide associated 
with cell-surface glycoproteins of certain mammalian and non-mammalian cells. The 
saccharide is not expressed by humans and anti-αGal antibodies account for ~1% of the 
total circulating antibodies in sera as a result of our constant exposition to the antigen 
from food and intestinal flora. Our interest in αGal relies on its involvement in a variety 
of pathologies including red meat allergy, hyperacute xenotransplant rejection, and 
parasitic and bacterial infections. In particular, we have an interest in developing 
structurally simple glycomimetics for engaging in high-affinity binding Gal-recognizing 
receptors such as the human anti-Gal IgG antibody and the Clostridium difficile toxins 
TcdA and TcdB in order to develop Gal based vaccine adjuvants and novel anti-infective 
therapies respectively. This communication presents our progress towards the synthesis 
of fluorinated Gal analogues as glycomimetics for their further applications to these 
goals. Apart from the role of carbohydrates in immune response, energy storage and as 
structural building blocks they are also involved in various other biological activities and 
many processes including cell-cell communication, immune response, fertilization, 
protein recycling, infection, among many others. The success of protein-carbohydrate 
interactions is conditioned to the fulfillment of conformational requirements imposed by 
the recognition site in the protein over the, inherently flexible, carbohydrate ligand. 
Hence, the study of the conformational preferences of saccharides is fundamental for the 
understanding of protein-carbohydrate interactions. In the second half of this thesis, we 
describe the results of the conformational study of rutinose (Rha(16)GlcOR) 
glycosides. In particular, we centered our study on how the nature of the aglycone 
substituent can modulate the conformational equilibria around the interglycosidic 
linkage. Given the inherent flexibility of the (16) linkage, the hydrophobic nature of the 
rhamnose moiety, and the simplicity of the NMR spectra, rutinose constitutes a 
convenient model saccharide for performing these studies. The spectroscopic evidence 
gathered suggest the existence of an effect that could be used in the rational design of 
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SYNTHESIS OF αGAL GLYCOMIMETICS FOR 




1.1. Biological roles of carbohydrates and their potential in biomedicine 
Carbohydrates are complex molecules which are ubiquitous in all living systems. The 
biological function of saccharides is vast, and it is not restricted to their classical roles of 
energy storage and structural units. The structural complexity of carbohydrates confers 
them a unique capacity to codify biological information. In fact, the molecular recognition 
of sugars by protein receptors is a key step in many biological processes including cell-cell 
communication, pathogenesis, immune response, cell differentiation, modulation of 
protein and lipid function, among many others.1 Carbohydrates are structurally diverse 
polymers giving a large number of isomers for a given sequence. Compared with peptides 
composed by equal number of monomers, there are more combinations possible for 
sugars given the polyfunctional nature of the respective monomers. While the structure 
of peptide polymers is restricted to linear architectures, with amide bond formation 
limited to -amine and the carboxylic acid, saccharides can generate linear and branched 
polymers containing glycosidic bonds that can be presented in several configurations. The 
higher structural diversity that can be found in carbohydrate polymers arises from the 
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possibility to make glycosidic bonds with at least three different hydroxyl groups; the 
creation of a new stereogenic center that can generate two types of anomers; and, in the 
case of pentoses and hexoses, the possibility to form pyranose and furanose rings. In 
addition, oligosaccharides are typically more flexible than proteins and peptides and can 
generate several conformational families adding more complexity to their solution 
structures.2 
Glycans associated with cell surface glycoconjugates are typically recognized by protein 
receptors leading the initiation of biological functions.3 Among the processes that include 
protein-carbohydrate interactions as part of the signaling cascade are cell adhesion, as in 
the case of white cell recruitment in inflammation; the physical stabilization of tissue 
interfaces, as in the case of dystroglycan and muscular integrity; the initiation of infection, 
as in the case of viral and bacterial toxin fusion with cell membranes; etc. During the last 
decades, an increasing interest in obtaining pure and structurally well-defined glycans has 
gained significance in the biological sciences and has stimulated the search for effective 
and high-yielding synthetic methods for preparing complex glycans and enabling the 
study of carbohydrate function. The success of these efforts is testified by the birth of a 
new paradigm about the function of glycans where these biomolecules are regarded as 
molecular codifiers of biological information, a paradigm also known as the glycocode.3  
1.2. Carbohydrate antigens 
An area of special interest is the study of the role of glycans in immune response. The 
surface of most prokaryotic and eukaryotic cells is heavily decorated with a glycocalyx 
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made primarily of protein- and lipid-conjugated glycans in addition to polysaccharides.4 
The structure of these glycans are part of the molecular signature of organisms such as 
bacteria, archaea, protozoa. Strain classifications are normally based on the structure of 
the glycocalyx. This dense superficial layer of carbohydrates, constitute a first line of 
recognition that is involved in innate and adaptive immune responses.5 Compared with 
proteins, carbohydrate antigens are more difficult to obtain in the laboratory since the 
structure of glycans is not encoded directly in the genome and their isolation from cells 
is, in general, a tedious and cost-ineffective process.6 Hence, the need for efficient 
synthetic methods aimed to prepare complex carbohydrate antigens is imperative for 
advancing in the study of carbohydrate immunology and for the future development of 
carbohydrate-based immunotherapies. The structural complexity of carbohydrate 
antigens, and glycans in general, represents an appealing challenge to the synthetic 
chemist. Currently, synthetic methodology for preparing any existing glycosidic linkage is 
available, however, there is still a need for cost-effective methods with the potential to 
generate bioactive glycans on a mass scale. This problem does not seem to be easily 
addressable given the inherent relationship between structural complexity and synthetic 
cost. An attractive alternative towards this objective is the design of structurally simple 
glycomimetics capable to elicit the same, or equivalent, function of complex glycans. In 
the case of antigens, a glycomimetic should be capable to elicit cross-reactive antibodies 





1.3. -Gal or Galili epitope
A remarkable carbohydrate antigen is αGal, also known as the Galili epitope. αGal is found 
associated with cell surface glycoconjugates of various protozoal parasites such as 
Trypanosoma cruzi (Chagas disease)8-10, Plasmodium falciparum (Malaria),11 and 
Leishmania spp. (Leishmaniasis),8, 12 and various bacterial species including pathogenic 
Mycobacterium tuberculosis (Tuberculosis),13 and Clostridium difficile (diarrhea and 
colitis). In addition, recent findings has connected the αGal antigen with tick-bite 
associated red meat allergy where exposure to αGal glycoconjugates from tick bites9, 14 
elicit hypersensitization to this antigen resulting in allergy to the consumption of red meat 
products. This condition has recently been renamed as Gal syndrome. 
Gal or Galili epitope, a name given to both the Gal-α-1,3-Gal disaccharide and Gal--1,3-
Gal-1,4-GlcNAc trisaccharide12, is a naturally occurring carbohydrate and it is 
associated with cell-surface glycoproteins of certain mammalian and non-mammalian 
cells.15, 16 The αGal epitope (Gal-α-1,3-Gal) is a common type-2 terminus glycan 
abundantly synthesized on lipids and proteins of non-primate mammals and New World 
monkeys through glycosylation via (1,3)-galactosyl transferase.17, 18 The epitope is 
however found to be absent in humans, apes and Old World monkeys.19 In these 
organisms the gene encoding for (1,3)-galactosyl transferase is silenced as a 
consequence of a hypothetical natural selection event carried out by a viral infection over 
early hominids.16, 20, 21 (1,3)-galactosyl transferase is responsible for catalyzing the -
galactosylation on the position 3 of terminal galactose acceptors. Typical substrates of 
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this enzyme are glycoproteins and glycolipids ended by lactose (Gal-β-1,4-GlcNAc-R) and 
N-acetyl lactosamine (Gal-β-1,4-GlcNAc-R).14 The inactivation of the (1,3)-galactosyl 
transferase gene in humans, ancestral Old World monkeys and apes is a unique event in 
mammalian evolution as it was followed by production of large amounts of the natural 
anti-αGal antibody against the eliminated Gal epitope.9 Our system is, however, 
exposed to Gal epitopes from food intake (red meats) and natural bacterial flora. This 
constant exposure leads to development of immune response against αGal. Structure of 






























































Figure 1.1. Major  gal epitopes: A: Gal disaccharide epitope (Gal-α-1,3-Gal-OR), B: 
isoglobotriaose (Gal--1,3-Gal1,4-Glc-OR’), C: Gal xenoantigen Gal--1,3-Gal-1,4-GlcNAc-
OR’, D: Pentaose Galili antigen (Gal--1,3-Gal--1,4-GlcNAc-1,3-Gal-1,4-Glc-OR) 
 
1.4. Anti-Gal Antibody 
Normal bacterial flora populating the gastrointestinal tract such as Escherichia coli, and 
bacteria of the genus Serratia, Salmonella, and Klebsiella express surface glycoconjugates 
displaying Gal. This results in a constant exposure to Gal epitopes leading to a steady 
production of anti-Gal antibodies by B cells residing in the lymphoid tissue lining the 
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gastrointestinal tract. Circulating anti-Gal antibody accounts for the most abundant type 
of immunoglobulin in human blood and 9, 12, 19, 22, 23 about 1% of B cells produce anti-Gal 
antibodies17 being IgG, IgM and IgA the predominant isotypes in serum whereas IgA and, 
to a lesser extent, IgG are the predominating isotypes in human secretions such as 
colostrum, milk, bile, and saliva. Human anti-Gal antibody is encoded by several heavy-
chain genes primarily of the VH3 immunoglobulin gene family.17, 19 Since the anti-Gal 
antibody production is constant along lifetime, anti-Gal is an attractive target for 
studying the immunology of carbohydrate and glycomimetic antigens and can be 
harnessed for a variety of biomedical applications.9  
Our interest in Gal lies in the opportunity that this antigen offers for developing 
carbohydrate-based drugs for a variety of biomedical applications including 
immunotherapies for allergy and neglected parasitic diseases, and the development of 
adjuvants for boosting the efficacy of vaccines.   
1.5. Binding site of α-Gal epitope (anti-gal antibody binding pocket) 
The epitope recognized by the anti-Gal antibody is the Gal--1,3-Gal disaccharide and 
the binding affinity is dependent on the nature and number of the subsequent 
saccharides. The affinity of the free trisaccharide Gal-1,3-Gal--1,4-GlcNAc is found to 
be ~7-fold higher compared with the disaccharide epitope.17 The inhibition of >80% of 
anti-Gal antibody is achieved by an Gal-disaccharide concentration of approximately 
3.3 mM whereas that of Gal-trisaccharide Gal- 1,3-Gal--1,4-Glc and Gal-1,3-Gal--
1,4-GlcNAc-OR’ is 1.0 mM. The association affinities of the trisaccharide and disaccharide 
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were found to be 6x106 M-1  and 5x105 M-1 respectively.24 The recognition of Gal epitopes 
by anti-Gal antibodies is primarily effected via direct polar contacts with hydroxyl groups 
located in the terminal galactose units (Gal disaccharide epitope) and, to a lesser extent, 
with polar contacts with hydroxyls situated in the third sugar. Thus, the nature of the 
antigen recognized by anti-Gal is an Gal-containing trisaccharide fragment.9, 19 
1.6. Biomedical relevance of the αGal antigen and the anti-Gal antibody 
Gal antigen and the anti-Gal antibody have an outstanding, yet underexplored, 
potential for developing therapies aimed to modulate immune responses. Since the 
epitope is expressed in several pathogenic microorganisms, it is an attractive antigen for 
developing broad-spectrum vaccine candidates by designing constructs that increase the 
concentration of anti-Gal immunoglobulins with a correlated protective effect. In fact, 
evidence suggest a correlation between low anti-Gal titers with major susceptibility to 
infectious diseases produced by Gal expressing pathogens such as tuberculosis and 
malaria. On the other hand, the elevated titers of anti-Gal antibodies in normal human 
sera provides the opportunity to develop vaccine adjuvants based on Gal via 
engagement of the circulating anti-Gal IgG and promotion of T helper cell mediated 
immune response. Furthermore, the involvement of Gal in red meat allergy stimulates 
the design of small molecule-based therapies for preventing allergic reactions. In the next 
paragraphs, we describe the potential applications of this unique carbohydrate antigen 




Gal as vaccine adjuvant  
The immunogenicity of a vaccine can be increased by including components that promote 
a stronger immune response. Such components are defined as adjuvants and are added 
to the vaccines as part of the formulation. An alternative strategy for boosting the efficacy 
of a vaccine by inducing a specific immune mechanism is the targeted delivery of the 
antigen to antigen-presenting cells (APC), such as dendritic cells and macrophages. Given 
the high concentration of anti-gal IgG antibody, it is reasonable to hypothesize that 
antigens tagged with  gal epitopes are susceptible to be recognized by anti-gal IgG and 
be subsequently endocytosed by APCs19, 25 
 
Figure 1.2. Targeting of vaccine candidate to antigen-presenting cell (APC) by the natural anti-Gal 
antibody.   
Figure 1.2 describes the hypothesized antigen-antibody interaction for increasing the 
efficacy of a vaccine candidate presenting the Gal epitope. Once the vaccine formulation 
carrying the Gal epitope, or Gal-mimetic, is administered into the system it is 
presumed to interact with anti-Gal IgG. The antigen-antibody complex so formed, 
known as immune complex, can be endocytosed by antigen presenting cells for further 
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presentation of the antigens as major histocompatibility complex-conjugates (MHC).19 
The internalization of the immune complexes by APC is accomplished via interaction 
between the Fc portion of immune-complexed anti-Gal antibody and Fc receptors 
(FcR) on the antigen presenting cell. The APC’s then migrate to regional lymph nodes 
where they present the MHC-conjugated antigens.9 This further leads to activation of 
specific CD4+ and CD8+ T-cells thus, leading to generation of long memory immune 
response. Our interest in this area is focused in study the potential use of the Gal antigen 
as vaccine adjuvant and the discovery of Gal glycomimetics able to elicit the same or 
equivalent adjuvant effect.  
Gal antigen for the development of vaccine candidates against parasitic diseases 
Gal epitopes has been found in the cell surface of several human parasites such as 
Trypanosoma cruzi (Chagas disease),10 Leishmania spp (leishmaniasis),12 Plasmodium 
falciparum (malaria), and evidence suggest its expression in Mycobacterium tuberculosis 
(tuberculosis).14,26, 13, 27 It has been shown that high levels of anti-αGal IgM and IgG 
isotypes provides resistance to the acquisition of Plasmodium falciparum or 
Mycobacterium tuberculosis infections11,13 providing the basis for future developments 
on Gal-based vaccine candidates directed to these pathogens.   
anti-Gal antibody mediated ‘autoimmune like’ phenomena in Chagas disease and 
Leishmaniasis. 
Chagas disease and leishmaniasis are marked by 10–30 fold higher anti-Gal titers 
compared with uninfected individuals.9, 10, 12 Gal epitopes are present on the cell surface 
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of T. cruzi and Leishmania spp. predominantly as glycoinositolphospholipids and 
lipophosphoglycans9 and anti-Gal binding of these epitopes induces complement-
mediated lysis of the pathogens contributing to lower parasitemia.8 However, this 
protection is not complete and escaping parasites penetrate into various tissues were 
they are protected. The intracellular parasites continue to produce, and release, Gal-
containing glycoconjugates stimulating the immune system to produce anti-Gal 
antibody which, in turn, interacts with the anti-Gal glycoconjugates concentrated in the 
tissue. This interaction leads to a localized ‘autoimmune-like’ inflammatory reactions 
characterized by the infiltration of macrophages and lymphocytes which results in 
cardiomyopathy, hepatomegaly, and megacolon, which are characteristic symptoms of 
acute and chronic Chagas disease and Leishmaniasis.8, 9  
Hence, we hypothesize that neutralization of circulating anti-Gal can mitigate the 
chronic inflammation undergone by patients of leishmaniasis and Chagas disease. Such 





Figure 1.3: Diagrammatic representation of reduction of anti-Gal mediated ‘autoimmune 
like’ phenomena in Chagas’ disease and Leishmaniasis using Gal epitopes/ Gal epitope 
mimetics 
 
Red meat allergy and Gal antigen 
Red meat allergy is the clinical manifestation of the hypersensitization to Gal as a result 
of an IgE response to the antigen. The origin of this hypersensitization has been linked to 
tick bites where the proposed allergen could be a salivary glycoconjugate expressing the 
epitope. Red meat allergy has been connected with the bites of different tick species 
around the world. In the US, the lone star tick (Amblyomma americanum), the vector that 
also transmits Lyme disease, is accounted for most of the reported cases. It is 
hypothesized that exposure to the Gal allergen from ticks induces the isotype switch of 
anti-Gal IgG  to anti-Gal IgE.28 After a exposure to Gal allergen, anti-Gal IgE develops 
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and binds to basophils and mast cells generating an “Gal-sensitized” status of the 
individual. Ingestion of red meat, which is found to contain Gal epitopes, crosslink 
basophil and mast cell bound anti-Gal IgE triggering cell degranulation and release of 
histamine cytokines, leukotrienes among other pro-inflammatory components (figure 1.5 
A). This results in the  29, 30  
 
Figure 1.4. Summary of alpha-gal sensitization leading to clinical symptoms of red meat allergy. 
 
Since the allergic reactions are triggered by the cross-linking of basophil or mast cell-
bound anti-Gal IgE by the allergen, an opportunity to develop anti-allergy drugs appears 
by targeting the allergen/IgE interaction (figure 1.5 B). This strategy has proven successful 
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in in vitro and in vivo models of peanut and penicillin allergies31, 32 and we hypothesize 
that this strategy based on IgE inhibitors can also be effective in preventing allergic 
reactions in patients with allergy to red meat.  
 
 
Figure 1.5. Mechanism of IgE-mediated allergic reaction (A) and inhibition of antigen/IgE 





The recognition of the Gal epitope by the circulating human anti-Gal IgG antibody has 
been partially characterized and information related to the structure of Gal and its 
affinity for the antibody is available. Peng et al.16 determined the key functional groups in 
the Gal--1,3-Gal--1,4-GlcNAc trisaccharide (figure 1.6) that are critical for maintaining 
the affinity for the antibody, presumably because of the direct contact that these groups 
make with the receptor. The main structure-affinity relationships reported are 
summarized below:  
 
Figure 1.6. Structure of the Gal antigen  Gal--1,3-Gal--1,4-GlcNAc and numbering system for 
carbohydrates. Numbers for the galactose moieties follows the same order that of GlcNAc, 
however, the distinction is made by adding single or double quotation marks for Gal II and Gal III 
respectively. 
 Gal-1,3-Gal (Gal(III)–Gal(II)) disaccharide binds with lower affinity than 
Gal1,3-Gal-1,4-GlcNAc trisaccharide 
 Replacement of GlcNAc by Glc leads to lower affinity  
 Elimination of hydroxyl groups over C2, C3 and C4 in terminal galactose (Gal(III)) 
result in affinity loss 
 Elimination of hydroxyl C6 on Gal(III) does not affect anti-Gal binding. 
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Based on these structure-affinity relationships we have designed Gal mimetic 
candidates for studying their affinities for the human anti-Gal antibody with the end 
goal of developing Gal-based immunoadjuvants and anti-Gal antibody inhibitors with 
applications in red meat allergy and Chagas disease autoimmune-like disorder. In 
addition, we also plan to evaluate the synthesized ligands as inhibitors of bacterial Gal 
receptors such as Clostridium difficile toxins TcdA and TcdB, as well as in the development 
of vaccine candidates for parasitic diseases.  
Given that the epitope recognized by the antibody is primarily the Gal--1,3-Gal moiety 
of the Gal trisaccharide28, we aim to prepare derivatives of this disaccharide as primary 
synthetic targets and perform iterative isosteric modifications for studying the effect over 
the affinity. We started our research by preparing analogues where hydroxyl groups C4 
and C6 groups are replaced with fluorine, a standard hydroxyl isostere. The structure of 
the proposed Gal mimetics is shown in figure 1.7. The glycomimetic candidates have 
been designed including an amino functionalized aglycone for their further 
bioconjugation to protein carriers, in order to generate substrates for immunization 
studies as well as for allowing the immobilization to sensor chips for performing affinity 




Figure 1.7. Structure of the target fluorinated Gal analogues 
Scheme 1.1 and Scheme 1.2 shows the retrosynthetic analysis followed for designing the 
synthetic route for the target Gal mimetics 1, 2, 3 and 4. A key step for generating the 
C4 fluoro galactose core is the C4 epimerization of glucose. The C4 fluoro galactose donors 
22 and 27 will allow the access to the monosaccharide 1 via coupling with a 3-
aminopropanol aglycone and to the disaccharide 3 via coupling with the galactose 
acceptor 34. 
To prepare C4 and C6 fluorinated analogues of Gal, we should start by defining the route 
for generating the key C4 fluoro-galactose monosaccharide. The C4 epimerization of 
glucose via SN2 substitution of the equatorial hydroxyl is an attractive strategy proven 
effective by different authors.33-36 Another aspect to consider is the appropriate selection 
of protecting groups for directing the stereoselectivity of the glycosylation reactions to  
be performed using the synthesized donors. Given that the inter-glycosidic configuration 
of Gal disaccharide is  (the oxygen atom from the acceptor galactose is axially 
connected to the donor) we should then select non-participating protective groups as 
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substituent of the C2 hydroxyl. In addition, the selection of the solvent for running the 
glycosylation reactions should also be made considering the desired stereoselectivity. 
 





Scheme 1.2. Retrosynthetic analysis of -Gal derivatives 3 and 4. 
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2.1. Synthesis of fluorinated galactosyl thioglycoside donors 
 
Figure 1.8. Structure of the fluorinated galactosyl donors to be used in this work 
The preparation of the C4 monofluoro and C4, C6 difluorogalactose donors 22, 27, 24 and 
25 started from commercially available glucose penta-acetate 5 (scheme 1.3). The first 
step consisted in the formation of the respective thioglucosyl donor by glucosylation 
reaction of tolylmercaptan in DCM catalyzed by BF3Et2O at room temperature.34 This 
procedure afforded the thioglycoside donor 6 in 92% yield. Subsequently, the acetyl 
protecting groups of 7 were removed under typical transesterification conditions by 
treatment with NaOMe (catalytic amount) in MeOH at rt.35 The respective tetraol 7 was 
formed quantitatively. The hydroxyl groups on C4 and C6 were selectively protected as 
4,6-benzylidene acetal by the treatment of 7 with PhC(OMe)2 and CSA in dry DMF.34, 35 






Scheme 1.3 Synthesis of benzylidene intermediate 8: a) TolSH, BF3Et2O, CH2Cl2, 0oC; b) NaOMe, 
MeOH, rt; c) PhC(OMe)2, CSA, DMF, rt. 
 
Given the strategic value of having an intermediate with the positions of interest, C4 and 
C6, orthogonally protected, and considering literature reports related to the effect of 
sugar protecting groups over the efficiency of the C4 epimerization reactions 37-39, we 
decided to prepare two types of intermediates from 8 bearing ether and ester protecting 
groups. The installation of the benzyl (ether) protecting groups on C2 and C3 was 
accomplished by the treatment of 8 with NaH in dry DMF followed by the addition of 
BnBr.40 This procedure furnished the benzyl protected intermediate 9 in 86% yield. 
Benzoyl (ester) protected intermediate 10 was obtained in 65% yield from the treatment 
of 8 with BzCl in pyridine.  
 
Scheme 1.4 Protection of hydroxyls C2 and C3 as ether 9 and ester 10. a) BzCl, Py, DCM, rt; b) 




The preparation of the C4 hydroxyl derivative 11 was performed by the regioselective 
opening of the benzylidene ring on benzoyl adduct 10 under reductive conditions with 
Et3SiH in TFA.41 This procedure afforded the C4 hydroxyl adduct 11 in 70% yield. It is 
important noting that the regioselectivity of this reaction is driven by the basicity of the 
C4 hydroxyl. Protonation of C4 hydroxyl promotes the opening of the benzylidene ring 
and subsequent formation of a hemiacetal oxonium ion which is reduced in situ to benzyl 
ether by the silane reagent (scheme 1.6).  
 
Scheme 1.5. Benzylidene ring opening of 9 and 10. a) Et3SiH, TFA, DCM, b) TFA/H2O (9:1) 
Hydrolysis of the 4,6-benzylidene 10 in a TFA/H2O (9:1) mixture, afforded the diol 13 in 
quantitative yield. The next step is one of the most critical which involves the C4-
epimerization of glucose along with the substitution of the hydroxyl groups with fluorine 
atom to generate the subsequent C4 monofluorinated and the C4, C6 difluorinated 





Scheme 1.6. Mechanism for the regioselective 4,6-benzylidene ring opening.  
To generate a series of glycosyl donors and acceptors with orthogonal reactivity at the 
anomeric carbon, we decided to prepare the O-glycosides analogues 19 and 21. The 
anomeric oxygen on these compounds will put at our disposition a more stable glycoside 
towards electrophilic fluorinating reagents such as DAST. In addition, these new 
substrates can be used in future one-pot assembly of oligosaccharides combined with the 
thioglycoside donors previously synthesized. The new compounds were prepared using 
the same synthetic route for the preparation of thioglucosides. We opted for benzyl 
alcohol as aglycone because of the simplicity of the benzyl group removal by Pd-catalyzed 




Scheme 1.7. Synthesis of benzyl O-galactosides 19 and 21. a) BnOH, BF3Et2O, MeCN, 50-800C; b) 
NaOMe, MeOH, rt; c) PhC(OMe)2, CSA, DMF, rt; d) BzCl, Py, CH2Cl2, rt; e) Et3SiH, TFA, DCM; f) NaH, 
BnBr, DMF, 0oC to rt.  
 
We attempted the direct C4 fluorination of O-glycosides 19 and 21 by treating the 
substrates with DAST in DCM.42 This procedure did not afford the desired fluorinated 
compounds and no reaction was observed for both ester 19 and ether 21 protected 
substrates. 
 











































After this result, we focused our attention in the thioglycoside donors and tested a two-
step procedure involving the generation of a C4 triflate leaving group and its subsequent 
displacement by fluoride. The procedure starts with reacting a mono-deprotected sugar 
with Tf2O and pyridine in DCM at -78oC for installing the respective triflate leaving group. 
After the reaction is completed, normally within 40 minutes, the system is diluted with 
organic solvent and washed with 1M NaHCO3 and brine solution. The organic phase is 
subsequently concentrated and the crude triflate is re-dissolved in THF and reacted with 
TBAF. First, we explored this procedure on thioglucoside 11 in a small-scale reaction and 
the outcome probed positive, affording a compound with an 1H NMR spectra (figure 1.8) 
consistent with the desired fluorinated adduct. The repetition of this procedure on a 
large-scale afforded the desired compound 22 in 76% yield. 
 
Scheme 1.9. Synthesis of C-4 fluoro thiogalactoside donor 22. a) i. Tf2O, Py, CH2Cl2, -780C, 40 mins 
ii. TBAF, THF, rt, 30 mins 
 
The installation of the fluorine atom in the sugar ring is confirmed by the splitting pattern 
of the proton connected to C4. H4 appears as a double doublet with a large coupling 
constant of 50.1 Hz (figure 1.8.), attributed to the two-bond coupling between H-4 and 
19F (2JH4-F), and a second constant of 2.1 Hz, assigned to the coupling with either H-5 or H-
3. The third coupling constant expected for H-4 is too small to be detected by the 




Figure 1.9. 1H NMR spectra of sugar region of 4-Fluoro galactosyl thioglycoside 22. 
During our attempts to synthesize the C-4 fluoro derivative 22 in a large-scale, we found 
that the nature of the solvent used to dilute the triflate crude prior to the washing step 
can lead to the generation of major byproduct. If in this step EtOAc is used instead of 
DCM, the major isolated product is a non-fluorinated derivative with an inverted C-4 
stereocenter. 1H and 13C NMR spectrum of this product is shown in Figure 1.9, Figure 1.10. 
and Figure 1.11. In the proton experiment, no large coupling constants are observed that 
can be assigned to coupling with fluorine. Assignments of the proton identities by COSY 
experiments revealed that H-4 appears as a double doublet with J values of 3.0 Hz and < 
1.0 Hz, consistent with galactose configuration and confirming the inversion of the C4 
stereocenter. In addition, the presence of a new acetyl group in the structure can be 
inferred from the signature signals in the 1H NMR for the methyl group (2.20 ppm) and a 
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third carbonyl carbon in the 13C spectra. Given that H-4 is the most de-shielded proton in 
the 1H spectra, we propose that the new acetyl group is connected to C4 and the structure 
of the byproduct is that shown for compound 23. 
 





Figure 1.11. 1H NMR  spectra of 4-O-acetyl galactosyl thioglycoside 23. 
 




A plausible mechanism for explaining the formation of this 4-O-acetyl galactose derivative 
is shown in scheme 1.11. Since triflates are highly reactive leaving groups, its 
displacement by the nucleophilic attack of the EtOAc carbonyl generates the intermediate 
II that is subsequently attacked by a molecule of water for generating the acetate adduct 
23 plus a molecule of ethanol. 
 
Scheme 1.10. Proposed mechanism for the formation of the 4-O-acetyl galactosyl thioglycoside 
23. 
 
To explore an alternative method involving a less-reactive intermediate, we explored the 
reaction using MsCl instead of Tf2O given the lower reactivity of the mesylates, compared 
with triflates, as leaving groups. Two test reactions were performed over the mesylate 13 
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using TBAF and NaF as fluoride sources, but these attempts did not afford the desired 
compound even after 3 days of reaction. 
 
Scheme 1.11. Treatment of 13 with Mesylchloride, NaF and TBAF : a) MsCl 3.0 eq.,DCM, Pyridine, 
24hrs; b) NaF, DMF, TBAF, 3 days 
 
Given the positive result obtained for the Tf2O/TBAF system, we continued our synthesis 
using this method for preparing the fluoro-galactose donors.  
The target disaccharide core to be synthesized, Gal, connects two galactose residues via 
an  glycosidic bond. Then we should be careful with the nature of the protecting group 
positioned over C2, since this group can be decisive for the stereoselectivity of the 
glycosylation reaction. The substitution of C2 with esters, directs the selectivity of the 
glycosylation towards the formation of the  anomer as major product. This is because of 
the anchimeric assistance played by the carbonyl that leads to the formation of a reactive 
intermediate with the carbonyl occupying the axial plane, which leaves the equatorial 
plane available for a subsequent nucleophilic attach by the glycosyl acceptor. Ether 
protecting groups, in contrast, do not participate of this type of interaction and allows the 
nucleophilic attack from both equatorial and axial planes. Hence, the replacement of the 
benzyl protecting group on C2 by an ether, is necessary for favoring the -selectivity of 
the donor 22 in glycosylation reactions. 
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Removal of the benzoyl protecting groups on 22 was performed by treatment with 
NaOMe in MeOH. The installation of the benzyl ethers was accomplished using NaH as a 
base and BnBr as benzyl source in DMF(Scheme 1.13).  
 
Scheme 1.12. Protecting group exchange for C-4 fluoro thiogalactoside 22. a) NaOMe, MeOH, b) 
NaH, BnBr,DMF  
 
Benzyl protected donor 27 was also prepared via fluorination of the alcohol 12 using the 
Tf2O/TBAF system (scheme 1.14.). 
 
Scheme 1.13. Synthesis of fluorinated donor 27 via nucleophilic fluorination of alcohol 12. a) i. 
Tf2O, Py, DCM, ii. TBAF, THF 
 
2.2. Synthesis of galactosyl acceptor/donor 
Galactose acceptor 34 was prepared from tolyl thiogalactoside 28 as described in scheme 
1.15. Compound 28 was subjected to acetyl group removal by treatment with NaOMe in 
MeOH. The cis-dihydroxyl groups on C3 and C4 in the resulting tetraol 29 were 
regioselectively protected as acetonide by treating it with 2,2-dimethoxypropane and CSA 
in DMF. The remaining hydroxyl groups on C2 and C6 were then protected as benzoate 
esters by treating the acetonide 30 with BzCl and pyridine in DCM. Hydroxyl groups on C3 
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and C4 were then deprotected by the hydrolysis of the acetonide ketal in TFA/H2O (9:1). 
The selective acetylation of the axial hydroxyl on C4 was accomplished in two steps. First, 
a hetero-orthoester from the diol 32 was formed by treating this intermediate with 1,1,1-
triethoxyethane and TsOH in toluene. Then, the orthoester was hydrolyzed under mild 
conditions by adding AcOH and water to the system and heating to 40oC.  
The 4-O-acetyl adduct 33 was then used as a donor in the glycosylation of N-benzyl-N-
carboxybenzyl-3-aminopropanol 37. The activation of the glycosyl donor with the 
NIS/TMSOTf system in the presence of 2 equivalents of the primary alcohol 37, afforded 
the desired glycoside 34 in 89% yield. The possible disaccharide byproduct expected from 
the self-glycosylation on C-3 was not observed given the better nucleophilicity and higher 
concentration of the primary alcohol of the aglycone.  
 
Scheme 1.14. Synthesis of acceptor 34. a) NaOMe, MeOH, rt; b) (CH3)2C(OCH3)2, CSA, DMF  rt; c) 
BzCl, Py, rt; d) TFA, H2O, rt; e) (EtO)3CCH3, p-TsOH, Tol., rt. then AcOH, H2O, 40oC; f) 37, NIS, 




2.3. Synthesis of N-benzyl-N-carboxybenzyl-3-amino propanol aglycone 25 
The aglycone structure was selected based on the future applications of the Gal 
glycomimetics. Since our primary interest is the utilization of these ligands on 
immunological studies, this requires the availability of a reactive functional group for the 
conjugation of these substrates to protein or lipid carriers. Amines are among the most 
versatile and widely used functional groups for this purpose. The coupling of amines to 
carboxylic acids allows not only the direct attachment of ligands to protein carriers but 
also allows the installation of different functional groups, such as alkynes, azides, biotin, 
etc. for biorthogonal conjugation reactions. Therefore, we selected the amine group as 
the reactive functional group, and we installed it in our glycomimetic candidates as part 
of the aglycone chain. The N-protected aglycone 37 was prepared from 3-aminopropanol 
in two steps (Scheme 1.16.). First, the amine group is protected as benzyl amine via 
reductive amination of benzaldehyde. Then, the isolated product 36 is reacted with CbzCl 
and pyridine in DCM to install the second protecting group over the secondary amine. 
Both Cbz and Bn groups can be cleaved by Pd-catalyzed hydrogenolysis. The protected 
aglycone 37 was isolated in 98% from the two steps.  
 
Scheme 1.15. Synthesis of N-protected aglycone 37. a) i. PhCHO, MeOH, HC(OMe)3, 0oC ii. NaBH4, 





2.4. Synthesis of 4-fluoro galactosides 
The presence of the fluorine atoms in the sugar rings have a deactivating effect on the 
reactivity of the donors towards activation given that the electronegativity of fluorine 
destabilizes the oxocarbenium intermediate generated during the activation. In contrast, 
benzyl ether protecting groups have an activating effect due to their electron donating 
character (scheme 1.17.). Therefore, when choosing an activating system for 
glycosylation reactions, attention must be paid to the reactivity of the donor and highly 
reactive activating systems should be selected for activating low reactivity (or disarmed) 
donors. With these considerations, we decided to select an activating system that will 
secure enough reactivity for activating our fluorinated donors and the NIS/TMSOTf 





























Scheme 1.16. The reactivity of glycosyl donors is determined by the stability of the oxocarbenium 
intermediate generated from the activation. Donors protected with electron-withdrawing 
substituents are less reactive and require more aggressive activating reagents.  
 
The selection of the solvent is relevant for directing the stereoselectivity of the 
glycosylation reaction and the formation of axial glycosides is normally favored if 
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ethereal solvents are used for running the reaction. Ethereal solvents, such as diethyl 
ether, dioxane, and tetrahydrofuran, can interact with the oxocarbenium intermediate by 
generating a transient covalent bond and occupying the equatorial position in the 
anomeric center. Consequently, a nucleophile will preferentially attack the plane 
leading to the respective glycoside (scheme 1.18.) 
 
 
Scheme 1.17. Control of the stereoselectivity of glycosylation reactions by the solvent. Ethereal 
solvents favor the formation of -linkages.  
 
The synthesis of the -glycoside 38 was accomplished by activating the donor 27 with 
NIS/TMSOTf in the presence of the primary alcohol 37 in Et2O. We gladly observed that 
the product 38 was obtained in an excellent yield (85%) indicating that the NIS/TMSOTf 
combination is reactive enough for the efficient activation of the fluorinated donors and 
afforded, as expected, the  anomer as unique compound. The  stereoisomer was not 




Scheme 1.18. Synthesis of glycosides 38. a) NIS, TMSOTf, Et2O, -300C, 30 min. 
2.5. Synthesis of fluorinated analogues of Gal disaccharide 
To generate the Gal disaccharide mono- and di-fluorinated cores 40 and 41, we 
envisaged a strategy based on the glycosylation of 34 with the benzylidene-protected 
thioglucoside donor 9. The center of this strategy is the preparation of the key 
intermediate 42 for enabling the synthesis of 40 and 41 via C4 epimerization/fluorination 
strategy. The activation of 9 with NIS/TMSOTf in Et2O in the presence of the acceptor, 
afforded the respective glucose disaccharide 42 in 89% yield. We then attempted the 
regioselective reductive opening of the benzylidene ring on this substrate by treating it 
with Et3SiH and TFA in DCM. The reaction outcome was a complex mixture of products 
not possible to resolve by chromatography.  
 






































Scheme 1.19. Alternative route for synthesis of disaccharides 40 and 41. a) NIS, TMSOTf, Et2O,               -
20oC; b) Et3SiH, TFA, DCM  
 
Figure 1.14. 1H NMR (CDCl3, 400 MHz) of disaccharide 42 
The glycosylation using fluorinated thioglycoside donors activated by the NIS/TMSOTf 
system proved effective for the high yield formation of glycosides and saccharides. The 
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reaction showed a high stereoselective control favoring the formation of the desired  
glycosidic bonds. The use of Et2O is assumed to contribute to the control of the 
stereoselectivity.  
The results of this work have demonstrated that the stereoselective synthesis of 
fluorinated analogues of the Gal antigen is feasible when using fluorinated thioglycoside 
donors. The future work will be centered in using this methodology for preparing the 




3. Future work 
We will continue our research program by focusing on the synthesis of the remaining 
mono- and di-fluorinated monosaccharide 39 and disaccharides 40 and 41 by 
glycosylation of acceptors 24 and 25 respectively with 34. Fluorination will be performed 
using two-steps procedures involving the generation of a C4 triflate leaving group and the 
subsequent treatment with fluoride using TBAF as fluorinating agent. (Scheme 1.21.) 
 
Scheme 1.20. Proposed synthesis of C4 fluoro thiogalactoside donor 24 and 25. a) installation of 
triflate leaving group by treatment with Tf2O/Py in DCM at -780C then TBAF in THF at rt. 
 
The synthesis of the -glycosides 39 will be attempted by using the activating system 
NIS/TMSOTf in Et2O. (Scheme 1.22.) 
 
Scheme 1.21. Proposed synthesis of glycosides 39. The activation of the difluorinated donor 24 




Gal disaccharide analogues 40 and 41 will be prepared by glycosylation of acceptor 34 
with donors 27 and 25 respectively (scheme 1.23.). The activation system to be used is 
NIS/TMSOTf and the reaction will be performed in Et2O for inducing solvent-mediated -
stereoselectivity. The disaccharides 40 and 41 will be isolated and  selectivity of the 
disaccharides 40 and 41 obtained will be determined, respectively.  
 
Scheme 1.22. Proposed synthesis of disaccharides 40 and 41. a) 27, NIS/TMSOTf, Et2O, -20oC. b) 
25, NIS/TMSOTf, Et2O, -20oC. 
 
After completing the synthesis of all four protected fluorinated saccharides 38, 39, 40 and 
41 the final step is the deprotection of the saccharides. Acetyl (Ac) and benzoyl (Bz) ester 
protecting groups will be removed by treatment with sodium methoxide in methanol or 
methanolic solution of ammonia. Benzyl ethers (Bn) will be cleaved by catalytic 
hydrogenolysis using Pd/C catalyst and hydrogen atmosphere. In this way, we expect to 
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obtain the corresponding fluorinated Gal mono and disaccharides 1, 2, 3 and 4. (Scheme 
1.24.)  
 
Scheme 1.23. Deprotection of ether and ester protected fluorinated Gal analogues 1-4. Ester 
removal (Ac or Bz): NaOMe, MeOH, or NH3 in MeOH; Benzyl ether removal: H2, Pd/C, EtOH 
 
The affinity of the synthesized Gal analogs for anti-Gal antibodies, and other receptors, 
will be determined as the respective dissociation constants (Kd) using the biophysical 





4. Experimental Section 
Commercially available carbohydrate starting materials were purchased from Carbosynth 
Ltd. All other commercial reagents and dry solvents were purchased from TCI, Across or 
Alpha Aesar. Chemicals and solvents were used without previous purification. Normal 
phase flash chromatography was done using SiliaFlash irregular silica gel F60, 40-63 m, 
60 Å (Silicycle) in glass columns and air pressure. NMR spectroscopy (1H, 13C, COSY, HSQC) 
were recorded in a Bruker Avance 400 spectrometer at St. John’s University. 
Procedures and experimental data of synthesized compounds 
S-pTolyl-2,3,4,6-tetra-O-acetylglucoside (6): Glucose pentaacetate 5 
(10.07 g, 25.7 mmol) and tolylmercaptan (6.38 g, 51.4 mmol) were 
dissolved in dry DCM (52.0 mL) and cooled to 0oC. BF3Et2O (3.17 mL, 25.7 mmol) was 
added dropwise and the solution was warmed to rt under stirring. After 5 hours of TLC 
shows total consumption of the starting material and the reaction was cooled to 0oC and 
quenched with triethylamine (4.0 mL). After 15 minutes of stirring at 0oC, the volatiles 
were removed in vacuum and the crude purified by flash chromatography using SiO2 as 
stationary phase and EtOAc/Hexanes mixture (3:7) as eluent. Thioglycoside 6 (9.23 g, 19.6 
mmol, 91.6%) was isolated as a waxy white solid. Compound identity was confirmed by 
comparison of 1H and 13C NMR spectra data with previously reported data. 43 1H NMR 
(CDCl3, 400 MHz): 7.39(d, J = 8.1 Hz, 2H), 7.12 (d, J = 8.1 Hz, 2H), 5.20 (dd, J = 9.3 and 
9.3 Hz, H-3), 5.02 (dd, J = 9.8 and 9.6 Hz, H-4), 4.93 (dd, J = 10.0 and 9.3 Hz, H-2), 4.63 
(d, J = 10.0 Hz, H-1), 4.19 (dd, J = 4.8 and 2.7 Hz, H-6), 4.13 (dd, J = 6.3 and 11.3 Hz, H-
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6’), 3.93 (m, J = 1.0, H-5), 2.35 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 2.01 (s, 3H), 1.98 
(s, 3H). 13C NMR (100MHz, CDCl3) δ 132.8 ,128.6 , 84.8 , 73.9 , 67.2 , 61.0 , 19.6.  
S-pTolyl glucoside (7): Thioglycoside 6 (12.1 g, 26.6 mmol) was 
dissolved in methanol (37.0 mL) and sodium methoxide (100 mg) 
was added. The suspension was stirred at r.t. for 24 hours which is enough time for the 
trans-esterification reaction to be completed (shown by TLC analysis). The system was 
then neutralized with Amberlyst IR-120+ resin followed by filtration. Methanol was 
removed in vacuo with rotary evaporator and the crude dried under high vacuum in a 
Schlenk line for 24 hours prior to use. Structure of tetraol 7 was confirmed by comparison 
of its 1H and 13C NMR spectra with previously reported data.44 1H NMR (CDCl3, 400 MHz): 
7.48 (d, J = 8.2 Hz, 2H), 7.14 (d, J = 7.9, 2H), 4.52 (d, J = 9.8 Hz, H-1), 3.87(dd, J =1.6 
Hz and 1.9 Hz, H-4), 3.67 (m, H-5), 3.38 (dd, J = 8.6 Hz and 8.6 Hz, H-3), 3.29 (m, H-6 
and H-6’), 3.19 (dd, J = 9.6 and 8.8 Hz, H-2),  2.33 (s, 3H). 13C NMR (100 MHz, MeOD) δ 
137.4, 132.1, 129.8, 129.1, 88.3, 80.7, 78.3, 72.3, 69.9, 61.5, 48.2, 48.0, 47.8, 47.6, 47.4, 
47.2, 46.9, 19.7.  
 S-pTolyl-,4,6-benzylideneglucoside (8): S-pTolyl glucoside (7) 
(5.45 g, 18.1 mmol) and benzaldehyde dimethoxyacetal (4.05 
mL, 27.1 mmol) are dissolved in dry DMF (36.2 mL) at r.t. followed by the addition of 
camphorsulfonic acid (21.02 mg, 0.90 mmol). The reaction is stirred for 18 hours and 
quenched by addition of Et3N (2.0 mL). System is diluted with DCM, transferred to a 
separation funnel, and washed with water. The organic layer is collected, dried over 
Na2SO4, filtered and the volatiles removed in vacuo. Benzylidene adduct is purified by 
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flash chromatography using SiO2 as stationary phase and EtOAc/Hexane (1:5) mixture as 
eluent. Chromatography afforded compound 8 (8.33 g, 25.4 mmol, 99%) as a waxy white 
solid. Compound identity was confirmed by comparison of 1H and 13C NMR spectra data 
with previously reported data.45 1H NMR (CDCl3, 400 MHz): 1H NMR (400 MHz, CDCl3) δ 
7.52 – 7.44 (m, 4H), 7.42 – 7.34 (m, 3H), 7.14 (dd, J = 20.5, 7.6 Hz, 2H), 4.60 (d, J = 9.7 Hz, 
H-1), 4.40 (dd, J = 10.4, 4.2 Hz, H-4), 4.14 (dd, J = 7.1 Hz and 10 Hz, H-2), 3.87 (t, J = 8.6 Hz, 
H-6), 3.83 – 3.76 (m, H-3), 3.58 – 3.49 (m, H-6’), 3.45 (dd, J = 9.1 Hz and 10.0 Hz, H-5), 2.38 
(s, 1H). 13C NMR (101 MHz, CDCl3) δ 206.9, 152.8, 138.9, 136.9, 133.7, 129.9, 128.3, 126.3, 
125.6, 80.2, 77.4, 77.0, 76.7, 74.6, 72.5, 70.6, 68.6, 30.9, 21.2, 1.0.  
S-pTolyl-2,3-O-dibenzyl-4,6-benzylideneglucoside (9): S-pTolyl-
4,6-benzylideneglucoside (8) (8.10 g, 24.8 mmol) is dissolved in 
dry DMF (124.0 mL) and cooled to 0oC with an ice-bath. Sodium Hydride (1.78 g,  74.4 
mmol, 60% suspension in mineral oil) was added portion-wise and the resulting 
suspension was kept under vigorous stirring at 0oC for 20 minutes. Benzyl bromide (3.53 
mL, 29.76 mmol) was then added, and the system allowed warming to r.t. After 2 hours 
TLC analysis shows total consumption of the starting alcohol and the predominance of 
one single spot. The mixture was cooled again to 0oC, quenched by MeOH (10.0 mL) 
addition and transferred to a pear-shaped flask for solvent is removed in vacuo. The crude 
was then purified by flash chromatography over SiO2 and using EtOAc/Hexanes (1:4) 
mixture as eluent. Benzylated adduct 9 (0.14 g,  21.1 mmol, 86%) was isolated as a waxy 
white solid. Compound identity was confirmed by comparison of 1H and 13C NMR spectra 
data with previously reported data.46 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.28 (m, 19H), 
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7.12 (d, J = 8.0 Hz, 2H), 4.97 – 4.74 (m, 4H), 4.69 (d, J = 9.6 Hz, H-1), 4.38 (dd, J = 10.2, 4.6 
Hz, H-4), 3.84 (d, J = 8.8 Hz, H-6), 3.79 (d, J = 10.8 Hz, H-3), 3.68 (t, J = 9.2 Hz, H-6’), 3.49 
(d, J = 8.9 Hz, H-2), 3.45 (d, J = 5.3 Hz, H-5), 2.34 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 
206.98, 133.0, 129.8, 128.4, 128.3, 128.2, 128.1, 125.9, 83.1, 77.3, 77.2, 77.0, 76.7, 60.4, 
30.9, 14.2.  
 S-pTolyl-2,3-O-dibenzoyl-4,6-benzylideneglucoside (10): S-
pTolyl-4,6-benzylideneglucoside (8)  (1.02 g, 3.56 mmol) was 
dissolved in pyridine (11.9 mL) and benzoyl chloride (1.21 mL, 10.2 mmol) was added to 
the solution at r.t. After 8 hours of stirring TLC analysis shows total consumption of the 
starting material and the volatiles were removed in vacuo. Dibenzoylated adduct was 
then purified by flash silica gel chromatography using EtOAc/Hexanes mixture (1:4) as 
eluents. Compound 10 (1.35 g,  2.32 mmol 65%) was isolated as a white solid. Compound 
identity was confirmed by comparison of 1H and 13C NMR spectra with previously 
reported data.47 1H NMR (CDCl3, 400 MHz): 8.07-7.07 (m, Aromatic H's, 19H), dd, 
J = 7.3 and 9.6 Hz, H-3),  5.52 (s, 2H), 5.42 (dd, J = 9.8 and 9.3 Hz, H-2) , 4.95 (d, J = 
9.9 Hz, H-1), 4.43 (dd, J = 5.2 and 4.6 Hz, H-5), 3.86 (m, H-4 and H-6), 3.72 (dd, J= 4.8 
and 4.8 Hz, H-6’), 2.03 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 206.9, 129.7, 128.1, 126.1, 
79.6, 77.4, 77.1, 76.7, 40.2, 30.7, 19.2.  
 S-pTolyl-2,3-O-dibenzoyl-6-benzylglucoside (11): Benzylidene 10 
(2 g, 3.4 mmol) and Et3SiH (5.4 mL, 34.0 mmol) are dissolved in DCM 
(20.4 mL) at 0oC and TFA (2.62 mL, 34.0 mmol) is added. The reaction is allowed warming 
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to r.t and stirred for 5 hours which is enough time for reaction completion (TLC analysis 
shows total consumption of the starting benzylidene and the predominance of a high 
polarity spot). The mixture is then transferred to a pear-shaped flask and the volatiles 
removed in vacuo. The obtained crude is purified by flash chromatography using silica gel 
as stationary phase and EtOAc/Hex (3:7 mixtures as eluents. Alcohol 11 (1.33 mg, 2.27 
mmol, 67%) was isolated as colorless syrup. Compound identity was confirmed by 
comparison of 1H and 13C NMR spectra data with previously reported data.48 1H NMR 
(CDCl3, 400 MHz):  8.11 (d, J = 7.1 Hz, 1H), 7.95 (m, 4H), 7.49 (m, 3H), 7.36 (m, 9H), 7.06 
(d, J = 8.0 Hz, 2H), 5.44 (dd, J = 9.3 and 9.3 Hz, H-3), 5.39 (dd, J = 9.4 and 9.4 Hz, H-2), 4.86 
(d, J = 9.5 Hz, H-1), 4.63 (d, J = 11.8 Hz, 1H), 4.59 (d, J = 11.8 Hz, 1H), 3.93 (dd, J = 9.3 and 
9.3 Hz, H-4 ), 3.88 (m, 2H, H-6 and H-6’), 3.72 (ddd, J = 4.4, 4.4 and 9.2 Hz, H-5), 2.31 (s, 
3H). 13C NMR (100 MHz, CDCl3) δ 167.2, 165.2, 138.4, 137.8, 133.7, 133.5, 133.4, 133.3, 
130.2, 129.9, 129.8, 129.7, 129.4, 129.0, 128.5, 128.5, 128.4, 128.3, 127.8, 127.8, 86.3, 
78.9, 77.9, 77.3, 77.0, 76.7, 73.8, 70.8, 70.2, 70.1, 30.9, 21.2.  
S-pTolyl-2,3,6-O-dibenzylglucoside (12): Benzylidene 9 (2 g, 3.4 
mmol) and Et3SiH (5.4 mL, 34.0 mmol) are dissolved in DCM (20.4 
mL) at 0oC and TFA (2.62 mL, 34.0 mmol) is added. The reaction is allowed warming to r.t 
and stirred for 5 hours which is enough time for reaction completion (TLC analysis shows 
total consumption of the starting benzylidene and the predominance of a high polarity 
spot). The mixture is then transferred to a pear-shaped flask and the volatiles removed in 
vacuo. The obtained crude is purified by flash chromatography using silica gel as 
stationary phase and EtOAc/Hex (3:7 mixtures as eluents. Alcohol 6 (1.33 mg, 2.27 mmol, 
46 
 
67%) was isolated as colorless syrup. 1H NMR spectra of this compound was consisted 
with previously published data￼ 
S-pTolyl-2,3-O-dibenzoylglucoside (13): 4,6-Benzylidene glucoside 
10 (2.06 g, 3.54 mmol) was dissolved in a mixture of TFA/H2O (9:1, 
4.0 mL) at r.t. and stirred for 60 minutes. After that period TLC analysis shows complete 
consumption of the starting material. Then TFA and water were removed in vacuo with 
rotary evaporator and the crude diol was purified by flash chromatography with silica gel 
as stationary phase and EtOAc/Hex mixtures (1:1) as eluents. Compound 7 (1.24 g, 3.34 
mmol, 60%) was isolated as a white solid. Compound identity was confirmed by 
comparison of 1H and 13C NMR spectra data with previously reported data.￼   
O-benzyl-2,3,4,6-tetra-O-acetylglucoside (15): Glucose 
pentaacetate 5 (10.07 g, 25.7 mmol) and Benzyl alcohol ( 5.34 ml, 
51.4 mmol) were dissolved in dry Acetonitrile (77.1 mL) and BF3Et2O (1.58 mL, 12.85 
mmol) was added dropwise and the solution was refluxed at 50 – 800C under stirring. 
After 6 hours of TLC shows total consumption of the starting material and the reaction 
was cooled to 0oC and quenched with triethylamine (4.0 mL). After 15 minutes of stirring 
at 0oC, the volatiles were removed in vacuum and the crude purified by flash 
chromatography using SiO2 as stationary phase and EtOAc/Hexanes mixture (3:7) as 
eluent. O-acetylglycoside 15 (7.55 g, 17.2 mmol, 75.15%) was isolated as a waxy white 
solid. Compound identity was confirmed by comparison of 1H and 13C NMR spectra data 
with previously reported data.511 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.26 (m, 6H), 5.09 
(dd, J = 9.3 Hz and 6.1 Hz, H-4), 5.03 (dd, J = 8.5 Hz and 9.5 Hz, H-3), 4.99 (dd, J = 9.3 Hz 
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and 7.7 Hz, H-2), 4.82 (d, J = 12.3 Hz, 1H), 4.56 (d, J = 12.3 Hz, 1H), 4.48 (d, J = 7.9 Hz, H-
1), 4.21 (dd, J = 12.3, 4.7 Hz, H-6), 4.10 (dd, J = 12.3, 2.4 Hz, H-6’), 3.60 (ddd, J = 9.6, 4.6, 
2.4 Hz, H-5), 2.04 (s, 3H), 1.95 (s, 3H), 1.94 (s, 3H), 1.93 (s, 3H). 13C NMR (100 MHz, CDCl3) 
δ 170.7, 170.3, 169.4, 169.3, 140.9, 136.6, 128.6, 128.5, 128.1, 127.8, 127.7, 127.0, 99.3, 
77.3, 77.0, 76.7, 72.8, 71.8, 71.3, 70.7, 68.4, 65.4, 61.9, 20.8, 20.6, 1.0. 
O-benzylglucoside (16): O-benzyl-2,3,4,6-tetra-O-acetylglucoside 15 
(7.24 g, 15.9 mmol) was dissolved in methanol (30.0 mL) and sodium 
methoxide (100 mg) was added. The suspension was stirred at r.t. for 24 hours which is 
enough time for the trans-esterification reaction to be completed (shown by TLC analysis). 
The system was then neutralized with Amberlyst IR-120+ resin followed by filtration. 
Methanol was removed in vacuo with rotary evaporator and the crude dried under high 
vacuum in a Schlenk line for 24 hours prior to use. Structure of glucopyranoside 16 was 
confirmed by comparison of its 1H and 13C NMR spectra with previously reported data.51 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.18 (m, 5H), 4.75 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 11.4 
Hz, 1H), 4.29 (d, J = 5.6 Hz, 1H), 3.71 (s, 2H), 3.51 (s, 1H), 3.35 (s, 2H), 3.13 (s, 1H). 13C NMR 
(100 MHz, CDCl3) δ 136.0, 127.4, 127.1, 76.3, 76.2, 75.9, 75.7, 70.3, 59.4, 20.0, 13.2.  
O-benzyl-4,6-benzylideneglucoside (17): O-benzylglucoside 16 
(1.90 g, 7.0 mmol) and benzaldehyde dimethoxyacetal (1.57 mL, 
10.5 mmol) are dissolved in dry DMF (14.0 mL) at r.t. followed by the addition of 
camphorsulfonic acid (81.30 mg, 0.35 mmol). The reaction is stirred for 18 hours and 
quenched by addition of Et3N (2.0 mL). System is diluted with DCM, transferred to a 
separation funnel, and washed with water. The organic layer is collected, dried over 
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Na2SO4, filtered and the volatiles removed in vacuo. Benzylidene adduct is purified by 
flash chromatography using SiO2 as stationary phase and EtOAc/Hexane (3:7) mixture as 
eluent. Chromatography afforded compound 17 (2.125 g, 6.17 mmol, 86%) as a waxy 
white solid. confirmed by comparison of 1H and 13C NMR spectra data with previously 
reported data. 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.38 (m, Aromatic H’s, 10H), 4.96 (d, J 
= 11.6 Hz, 1H), 4.65 (d, J = 11.6 Hz, 1H), 4.53 (d, J = 7.7 Hz, H-1), 4.39 (dd, J = 10.5, 5.0 Hz, 
1H), 3.83 (m, 2H), 3.59 (m, 2H), 3.50 (m, 1H), 2.66 (s, 1H), 2.48 (s, 1H). 13C NMR (100 MHz, 
CDCl3) δ 206.9, 128.6, 128.4, 128.2, 126.7, 126.3, 102.1, 101.9, 80.6, 77.3, 77.2, 77.0, 76.7, 
74.6, 73.2, 68.7, 66.5, 30.9.51 
O-benzyl-2,3-O-benzoyl-4,6-benzylideneglucoside (18): 2,3-
Diol 17 (1.01 g, 2.92 mmol) was dissolved in pyridine (4.67 mL) 
and benzoyl chloride (1.01 mL, 8.76 mmol) was added to the solution at r.t. After 8 hours 
of stirring TLC analysis shows total consumption of the starting material and the volatiles 
were removed in vacuo. Dibenzoylated adduct was then purified by flash silica gel 
chromatography using EtOAc/Hexanes mixture (2:3) as eluents. Compound 18 (1.68 g,  
2.97 mmol 99%) was isolated as a white solid. Compound identity was confirmed by 
comparison of 1H and 13C NMR spectra with previously reported data. 1H NMR (400 MHz, 
CDCl3) δ 8.17 - 7.18 (m, 22H), 5.73 (dd, J = 9.6 Hz and 9.5 Hz, H-3), 5.56 (dd, J = 6.5 Hz and 
10.5 Hz, H-2), 4.91 (d, J = 12.5 Hz, 1H), 4.82 (d, J = 7.8 Hz, H-1), 4.68 (d, J = 12.5 Hz, 1H), 
4.46 (dd, J = 10.5, 4.9 Hz, -6H), 3.95 (dd, J = 9.3, 5.0 Hz,H-4), 3.91 (d, J = 5.0 Hz and 10.4 
Hz,H-6’), 3.67 (m, H-5). 13C NMR (100 MHz, CDCl3) δ 165.2, 162.4, 136.8, 136.5, 134.5, 
133.2, 133.1, 130.6, 129.9, 129.8, 129.4, 129.3, 129.0, 128.9, 128.4, 128.3, 128.2, 128.2, 
49 
 
127.9, 127.8, 126.7, 126.1, 101.5, 100.0, 78.8, 77.3, 77.2, 77.0, 76.7, 72.3, 72.1, 70.8, 68.7, 
66.6.52 
O-benzyl-2,3-O-benzoyl-6-O-benzylglucoside (19): Benzylidene 18 
(0.952 g, 1.68 mmol) and Et3SiH (2.68 mL, 34.0 mmol) are dissolved 
in DCM (20.4 mL) at 0oC and TFA (2.62 mL, 16.8 mmol) is added. The reaction is allowed 
warming to r.t and stirred for 5 hours which is enough time for reaction completion (TLC 
analysis shows total consumption of the starting benzylidene and the predominance of a 
high polarity spot). The mixture is then transferred to a pear-shaped flask and the volatiles 
removed in vacuo. The obtained crude is purified by flash chromatography using silica gel 
as stationary phase and EtOAc/Hex (3:7) mixtures as eluents. Alcohol 19 (0.60 g, 1.05 
mmol, 63%) was isolated as colorless syrup.  
O-benzyl-2,3-benzyl-4,6-O-benzylideneglucoside (20): 2,3-Diol 
18  (1.02 g, 2.96 mmol) is dissolved in dry DMF (14.8 mL) and 
cooled to 0oC with an ice-bath. Sodium Hydride (213 mg,  8.88 mmol, 60% suspension in 
mineral oil) was added portion-wise and the resulting suspension was kept under vigorous 
stirring at 0oC for 20 minutes. Benzyl bromide (0.421 mL, 3.55 mmol) was then added, and 
the system allowed warming to r.t. After 2 hours TLC analysis shows total consumption of 
the starting alcohol and the predominance of one single spot. The mixture was cooled 
again to 0oC, quenched by MeOH (10.0 mL) addition and transferred to a pear-shaped 
flask for solvent is removed in vacuo. The crude was then purified by flash 
chromatography over SiO2 and using EtOAc/Hexanes (2:3) mixture as eluent. Benzylated 
adduct 20 (1.6 g,  2.97 mmol, 99%) was isolated as a waxy white solid. Compound identity 
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was confirmed by comparison of 1H and 13C NMR spectra data with previously reported 
data.51 
O-benzyl-2,3,6-O-benzylideneglucoside (21): Benzylidene 20 (0.707 
g, 1.31 mmol) and Et3SiH (2.092 mL, 13.1 mmol) are dissolved in 
DCM (4.3 mL) at 0oC and TFA (1.01 mL, 13.1 mmol) is added. The reaction is allowed 
warming to r.t and stirred for 5 hours which is enough time for reaction completion (TLC 
analysis shows total consumption of the starting benzylidene and the predominance of a 
high polarity spot). The mixture is then transferred to a pear-shaped flask and the volatiles 
removed in vacuo. The obtained crude is purified by flash chromatography using silica gel 
as stationary phase and EtOAc/Hex (3:7) mixtures as eluents. Alcohol 21 (0.495 g, 0.92 
mmol, 70%) was isolated as colorless syrup. Compound identity was confirmed by 
comparison of 1H and 13C NMR spectra data with previously reported data.51  
S-pTolyl-2,3-O-benzoyl-6-O-benzyl-4-fluorogalactoside (22): To a 
solution of compound 11 (175 mg, 0.30 mmol) in DCM (870 L) was 
added pyridine (40 L). The resulting solution was cooled (-78oC) and stirred under argon, 
and Tf2O (73 L, 0.448 mmol) was added. The reaction mixture was warmed to room 
temperature and, after 40 min, TLC analysis (ethyl acetate–hexane, 2 : 3 v/v) showed 
complete conversion of starting material into triflate intermediate (Rf 0.88). The reaction 
mixture was diluted with DCM (10 ml) and was washed successively with saturated aq. 
sodium hydrogen carbonate (2 × 10 ml) and brine (2 × 10 ml). The organic phase was dried 
using sodium sulphate and concentrated to dryness in vacuum to yield a sticky yellow 
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solid. This compound was immediately dissolved in THF ( 900 L) stirred under argon, and 
TBAF solution (1.1 M in THF, dried over molecular sieves 4 Å; 250 L, mmol) was added. 
A color change from yellow to deep red was observed and immediate TLC analysis (ethyl 
acetate–cyclohexane, 2 : 3 v/v) showed complete conversion of the intermediate (Rf 0.88) 
into a major product (Rf 0.67). The reaction mixture was concentrated to dryness in 
vacuo, the resulting brown solid was dissolved in DCM (10 ml), and the solution was 
washed with brine (2 × 10 ml). The organic phase was dried (MgSO4) and concentrated to 
dryness in vacuo to yield a sticky yellow brown solid. Crude fluorinated analog 22 was 
purified by flash chromatography with silica gel as stationary phase and EtOAc/Hex 
mixtures (1:1) as eluents. Compound 22 (100.3 mg, 0.216 mmol, 57.3%) was isolated as a 
white solid. 1H NMR (CDCl3, 400 MHz) 7.97 - 7.07 (m, Aromatic H’s), 5.70 (dd, J = 9.9 Hz 
and 9.9 Hz, H-2), 5.36 (ddd, J = 2.1, 9.9 Hz and 27.6 (3JHF) Hz, H-3), 5.12 (dd, J = 2.1 and 
50.1 (2JHF) Hz, H-4), 4.88 (d, J = 9.9 Hz, H-1), 4.58 (s, 2H, PhCH2O),  3.94 (ddd, J = 6.5, 6.5 
and 26.7 (3JHF) Hz, H-5), 3.79 (m, H-6 and H-6’), 2.32 (s, 3H). 13C NMR (100 MHz, CDCl3) 
δ 206.9, 165.8, 165.1, 138.5, 137.7, 133.5, 133.4, 133.3, 129.9, 129.8, 129.7, 129.4, 128.9, 
128.5, 128.5, 128.4, 128.3, 127.9, 127.7, 87.3, 86.8, 85.5, 77.3, 77.0, 76.7, 76.3, 76.1, 73.7, 
73.6, 73.4, 67.9, 67.5, 30.9, 21.2.  
S-pTolyl-4-fluorogalactoside (26): Thioglycoside 22 (47.5 mg, 0.081 
mmol) was dissolved in methanol (0.5 mL) and sodium methoxide 
(0.1 mg) was added. The suspension was stirred at r.t. for 24 hours which is enough time 
for the trans-esterification reaction to be completed (shown by TLC analysis). The system 
was then neutralized with Amberlyst IR-120+ resin followed by filtration. Methanol was 
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removed in vacuo with rotary evaporator and the crude dried under high vacuum in a 
Schlenk line for 24 hours prior to use. Structure of deprotected fluorinated compound 30 
was confirmed by comparison of its 1H and 13C NMR spectra with previously reported 
data. 1H NMR (400 MHz, CDCl3) δ 8.05 -7.11 (m, Aromatic H’s, 4H), 4.86 (d, J = 49.0 Hz, H-
4), 4.46 (d, J = 9.2 Hz, H-1), 3.80 – 3.68 (m, 3H), 3.65 (d, J = 9.2 Hz, 2H), 1.25 (s, 3H). 13C 
NMR (100 MHz, CDCl3) δ 133.3, 132.9, 129.9, 129.6, 128.5, 128.4, 127.9, 127.7, 89.2, 88.5, 
87.4, 77.3, 77.0, 76.7, 76.4, 76.2, 73.7, 73.7, 73.6, 69.8, 67.8, 67.7, 60.4, 52.1, 31.6, 22.7, 
21.2, 14.2, 14.1. 
S-pTolyl-2,3,6-O-benzyl-4-fluorogalactoside (27): Alcohol 30 (30.1 
mg, 0.182 mmol) is dissolved in dry DMF (1.0 mL) and cooled to 0oC 
with an ice-bath. NaH (13.1 mg, 0.546 mmol, 60% suspension in mineral oil) was added 
portion-wise and the resulting suspension was kept under vigorous stirring at 0oC for 20 
minutes. Benzyl bromide (26 L, 0.21 mmol) was then added and the system allowed 
warming to r.t. After 4 hours TLC analysis shows total consumption of the starting alcohol 
and the predominance of one single spot. The mixture was cooled again to 0oC, quenched 
by MeOH (0.5 mL) addition and transferred to a pear-shaped flask for solvent removal 
with rotary evaporator. The crude was then purified by flash chromatography over SiO2 
and using EtOAc/Hexanes (1:9) mixture as eluent. Benzylated adduct 31 (22.5 mg, 0.051 
mmol, 75%) was isolated as a waxy white solid. 1H NMR (400 MHz, CDCl3) δ 7.36 (dd, J = 
12.6, 7.8 Hz, 4H), 7.31 – 7.15 (m, 13H), 7.00 (d, J = 7.8 Hz, 2H), 4.81 (d, J = 49.1 Hz, H-4), 
4.71 (d, J = 10.0 Hz, 1H), 4.69 – 4.57 (m, 1H), 4.51 (d, J = 9. Hz 1H), 3.74 – 3.62 (m, 1H), 
3.59 – 3.43 (m, 1H), 2.24 (s, 3H), 1.29 (d, J = 22.6 Hz, 2H), 0.85 – 0.60 (m, 4H). 13C NMR 
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(100 MHz, CDCl3) δ 138.2, 137.8, 137.8, 137.6, 132.7, 129.7, 129.4, 128.6, 128.5, 128.4, 
128.3, 127.9, 127.8, 127.8, 87.9, 86.7, 84.9, 81.2, 80.9, 77.3, 77.0, 76.9, 76.7, 75.9, 75.8, 
75.7, 73.7, 72.2, 67.8, 67.8, 36.6, 33.7, 31.9, 30.2, 29.7, 29.4, 26.7, 22.7, 21.1, 14.1. 
S-pTolyl-2,3,4,6-tetra-O-acetylgalactoside (28): Galactose 
pentaacetate 18 (13.6 g, 34.8 mmol) and tolylmercaptan (4.76 g, 
38.3 mmol) were dissolved in dry DCM (70.0 mL) and cooled to 0oC. BF3Et2O (1.3 mL, 10.4 
mmol) was added dropwise and the solution was allowed to warm to r.t. under stirring. 
After 5 hours of TLC shows total consumption of the starting material and the reaction 
was cooled to 0oC and quenched with triethylamine (5.0 mL). After 15 minutes of stirring 
at 0oC, the volatiles were removed in vacuo and the crude purified by flash 
chromatography using SiO2 as stationary phase and EtOAc/Hexanes mixture (3:7) as 
eluent. Thioglycoside 28 (14.4 g, 31.7 mmol, 91%) was isolated as a waxy white solid. 
Compound identity was confirmed by comparison of 1H and 13C NMR spectra data with 
previously reported data.10 
S-pTolylgalactoside (29): Thioglycoside 28 (12.1 g, 26.6 mmol) was 
dissolved in methanol (50.0 mL) and sodium methoxide (300.1 mg) 
was added. The suspension was stirred at r.t. for 24 hours which is enough time for the 
trans-esterification reaction to be completed (shown by TLC analysis). The system was 
then neutralized with Amberlyst IR-120+ resin followed by filtration. Methanol was 
removed in vacuo with rotary evaporator and the crude dried under high vacuum in a 
Schlenk line for 24 hours prior to use. Structure of tetraol 29 was confirmed by 
comparison of its 1H and 13C NMR spectra with previously reported data.53 
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S-pTolyl-3,4-acetonidegalactoside (30): Tetraol 29 (4.70 g, 17.3 
mmol) was dissolved in 2,2-dimethoxypropane (100.0 mL) at r.t. 
and camphor sulfonic acid (160.0 mg, 0.68 mmol) was added to the solution. After 48 
hours of stirring at r.t. TLC shows total consumption of the starting material and the 
predominance of 2 spots corresponding to the desired 3,4-acetonide and 3,4-acetonide-
6-hemiketal byproduct. Reaction was quenched by addition of Et3N (5.0 mL), the volatiles 
were removed in vacuo and the residue re-dissolved in EtOAc and percolated through a 
bed of silica gel. The mixture was then re-dissolved in a MeOH/H2O mixture (10:1, 50 mL) 
and refluxed until 6-hemiketal (top TLC spot) hydrolysis was complete (usually after 4 
hours of reflux). Acetonide was then purified by flash chromatography using SiO2 as 
stationary phase and EtOAc/Hexanes mixture (3:2) as eluent. The respective diol 30 (4.0 
g, 12.3 mmol, 71%) was isolated as a white solid. Compound identity was confirmed by 
comparison of 1H and 13C NMR spectra data with previously reported data.54 
S-pTolyl-3,4-acetonide-2,6-benzoylgalactoside (31): Diol 30 (4.0 g, 
12.3 mmol) was dissolved in pyridine (20.0 mL) and benzoyl 
chloride (4.3 mL, 37.0 mmol) was added to the solution at r.t. After 8 hours of stirring TLC 
analysis shows total consumption of the starting material and the volatiles were removed 
in vacuo. Dibenzoylated adduct was then purified by flash silica gel chromatography using 
EtOAc/Hexanes mixture (3:7) as eluents. Compound 31 (6.26 g, 11.7 mmol 95%) was 
isolated as a white solid. Compound identity was confirmed by comparison of 1H and 13C 
NMR spectra with previously reported data.10 
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S-pTolyl-2,6-benzoylgalactoside (32): Acetonide 31 (10.2 g, 19.1 
mmol) was dissolved in a mixture of TFA/H2O (9:1, 20.0 mL) at r.t. and 
stirred for 10 minutes. After that period TLC analysis shows complete consumption of the 
starting material. Then TFA and water were removed in vacuo with rotary evaporator and 
the crude diol was purified by flash chromatography with silica gel as stationary phase 
and EtOAc/Hexane mixtures (1:1) as eluents. Compound 32 (8.70 g, 17.6 mmol, 92%) was 
isolated as a white solid. 10 
S-pTolyl-4-acetyl-2,6-benzoylgalactoside (33): 3,4-Diol 32 (4.68 g, 9.5 
mmol), triethylorthoacetate (5.4 mL, 29.5 mmol) and 
camphorsulfonic acid were dissolved in dry CHCl3 (45.0 mL) and stirred at r.t. until the 
trans-esterification reaction was complete (TLC analysis). The galactose orthoester 
product was then partially hydrolyzed in situ by addition of MeCN/H2O (5:1, 5.0 mL) and 
stirring at r.t. After the reaction was complete, purification was performed by flash 
chromatography using SiO2 as stationary phase and EtOAc/Hexanes mixture (2:4) as 
eluent. 4-O-acetate 7 (4.8 g, 8.9 mmol, 94%) was obtained as a white solid. Compound 
identity was confirmed by comparison of 1H and 13C NMR spectra with previously 
reported data.10 
O-[3-(N-benzyl-N-carboxybenzyl)propyl]-4-acetyl-2,6-
benzoylgalactoside  (34): Monosaccharide 33 (885 mg, 
1.65 mmol) and Alcohol 25 (0.988 g, 3.3 mmol) were dissolved in Acetonitrile (6.6 mL) in 
the presence of 4 Å molecular sieves (200.0 mg). The suspension was stirred at r.t. for 15 
mins and then cooled to -20 - -30oC using dry ice. NIS (408.3 mg, 1.815 mmol) was then 
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added followed by TMSOTf (29.8 L, 0.165 mmol) and vigorous stirring was continued 
until total consumption of the donor was observed (TLC, 3 hours). Reaction was then 
diluted with ethyl acetate (5.0 mL), quenched with Et3N (1.0 mL), allowed to warm to r.t., 
filtered over a Celite® bed, transferred to a separation funnel and washed with NaS2O3. 
The organic fraction was dried over Na2SO4, the volatiles removed in vacuo and the crude 
purified by flash chromatography using silica gel as stationary phase and EtOAc/Hexanes 
(1:2) gradient as eluent solutions. Glycosylated monosaccharide 26 (787.3 mg, 1.08 
mmol,88.93% ) was isolated as a white solid.  
3-(N-benzyl-N-carboxybenzyl)propanol (37): To a solution of 
3-amino-1-propanol 35 (14.73 g, 196 mmol) in MeOH (49 mL) 
at 0°C were added HC(OMe)3 (21.50 mL, 196 mmol) and benzaldehyde (20 mL, 196 mmol). 
The reaction mixture was warmed to room temperature under an argon atmosphere. 
After stirring at the same temperature for 3.5 h, NaBH4 (7.41 g, 196 mmol)  as added at 
0°C. Then, the reaction mixture was stirred for 10 h at room temperature. After quenching 
the reaction mixture by adding H2O at 0°C, the resulting mixture was concentrated under 
reduced pressure and then diluted with CHCl3. The organic phase was separated, and the 
aqueous phase was extracted three times with CHCl3. The combined organic extracts 
were washed with brine, dried over MgSO4, filtered, and concentrated under reduced 
pressure. The crude material was used in the next reaction without further purification. 
To a solution of the crude material in CH2Cl2 (196 mL) and H2O (137.2 mL) was added 
K2CO3 (23.02 g, 166.6 mmol) at 0 °C. After the reaction mixture was stirred vigorously at 
room temperature for 10 min under an argon atmosphere, CbzCl (28.0 mL, 196 mmol) 
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was added at 0 °C over 60 min. After stirring at room temperature for 12 h under an argon 
atmosphere,  the reaction mixture was diluted with CH2Cl2and H2O. The organic phase 
was separated, and the aqueous phase was extracted three times with CH2Cl2. The 
combined organic extracts were washed with brine, dried over MgSO4, filtered, and 
concentrated under reduced pressure. The crude material was purified by silica gel flash 
column chromatography(EtOAc/n-hexane = 50 : 50) to afford N-(benzyl)benzyloxycarbo-
nyl 3-amino-1-propanol 25 (14.40 g, 98% in two steps) as a colorless oil. 1H NMR (400 
MHz, CDCl3)  7.38-7.28 (m, 8H), 7.19 - 7.18 (m, 2H), 5.19 (s, 2H), 4.47 (s, 2H), 3.55 (dd, J 
= 5.2 and 5.2, 2H), 3.45 (dd, J = 5.7 and 5.7, 2H), 1.65 (m, 2H). 13C NMR (100 MHz, CDCl3) 
δ 204.8, 155.3, 135.2, 134.2, 126.4, 126.3, 125.9, 125.8, 125.3, 125.2, 75.1, 75.0, 74.8, 
74.5, 65.5, 58.2, 56.3, 48.0, 40.7, 28.7, 27.9, 12.0. 
O-[3-(N-benzyl-N-carboxybenzyl)propyl]-2,3,6-benzyl-4-
fluorogalactoside (38): Monosaccharide 31 (9.1 mg, 
0.0162 mmol) and Alcohol 25 (9.7 mg, 3.3 mmol) were 
dissolved in diethylether (65.12 L) in the presence of 4 Å molecular sieves (1.0 mg). The 
suspension was stirred at r.t. for 15 mins and then cooled to -20 - -30oC using dry ice. NIS 
(4.0 mg, 0.0172 mmol) was then added followed by TMSOTf (0.3 L, 1.6 mol) and 
vigorous stirring was continued until total consumption of the donor was observed (TLC 
2 hours). Reaction was then diluted with ethyl acetate (5.0 mL), quenched with Et3N (0.5 
mL), allowed to warm to rt, filtered over a Celite® bed, transferred to a separation funnel 
and washed with NaS2O3. The organic fraction was dried over Na2SO4, the volatiles 
removed in vacuo and the crude purified by flash chromatography using silica gel as 
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stationary phase and EtOAc/Hexanes (1:2) gradient as eluent solutions. Glycosylated 
monosaccharide 38 ( 8.2 mg, 0.011 mmol, 90 % ) was isolated as a yellow solid. * 
Compound identity is pending to be confirmed by NMR. TLC analysis showed that this 
product has a lower Rf value respect to the donor 27 and higher Rf respect to alcohol 37. 
In addition, compound 38 stains strongly with H2SO4 and Ninhydrin (donor 27 stains with 
H2SO4 only) providing evidence of the successful installation of the aglycone. 
   S-pTolyl-2,3-O-dibenzyl-4,6-O-benzy 
lideneglucoside-1→4-O-[3-(N-benzyl-    
N-carboxybenzyl)propyl]-2,6-O-diben 
zoyl-4-O-acetylgalactoside (42): Monosacharide acceptor 26 (571.5 mg, 0.785 mmol) and 
donor 27 (653.3 mg, 1.17 mmol) were dissolved in Diethylether (3.2 mL) in the presence 
of 4Å molecular sieves (200.0 mg). The suspension was stirred at r.t. for 15 mins and then 
cooled to -20 - 30oC using dry ice. NIS (353.3 mg, 1.57 mmol) was then added followed by 
TMSOTf (14.2 L, 0.0785 mmol) and vigorous stirring was continued until total 
consumption of the donor was observed (TLC, 3 hours). Reaction was then diluted with 
ethyl acetate (5.0 mL), quenched with Et3N (1.0 mL), allowed to warm to r.t., filtered over 
a Celite® bed, transferred to a separation funnel and washed with NaS2O3. The organic 
fraction was dried over Na2SO4, the volatiles removed in vacuo and the crude purified by 
flash chromatography using silica gel as stationary phase and EtOAc/Hexanes (3:7) 
gradient as eluent solutions. Glycosylated disaccharide 28 (508.8 mg, 0.699 mmol, 89% ) 
was isolated as a white solid.  * The presence of the signature signals of the two anomeric 
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and benzylidene hydrogens in the 1H NMR spectra, provide evidence that this compound 













Figure 1.15. 1H NMR (CDCl3, 400 MHz) spectra of compound 6. 
 




Figure 1.17. 1H NMR (CDCl3, 400 MHz) spectra of compound 8. 
 




Figure 1.19. 1H NMR (CDCl3, 400 MHz) spectra of compound 10. 
 




Figure 1.21. 1H NMR (CDCl3, 400 MHz) spectra of compound 15. 
  




Figure 1.23. 1H NMR (CDCl3, 400 MHz) spectra of compound 17. 
 




Figure 1.25. 1H NMR (CDCl3, 400 MHz) spectra of compound 22. 
 




Figure 1.27. 1H NMR (CDCl3, 400 MHz) spectra of compound 27. 
 




Figure 1.29. 1H NMR (CDCl3, 400 MHz) spectra of compound 37. 
 









CONFORMATIONAL ANALYSIS OF RUTINOSE GLYCOSIDES 
1. Introduction 
The biological activity of carbohydrates extends far beyond their classical roles as energy 
sources or structural building blocks. Many biological processes such as cell 
differentiation, fertilization, cell-cell communication, infection, etc. involve the 
recognition of carbohydrate ligands by protein receptors as part of the signaling cascade. 
55 The specificity, and success, of these molecular recognition events depend on the 
fulfillment of well-defined geometric and conformational requirements in both receptor 
and ligand. In the case of carbohydrates, given their inherent flexibility, the 
conformational properties claim a higher share, in comparison with other classes of 
molecules, in determining the specificity and the affinity of the interaction. Hence, the 
study of the conformational properties of sugars is paramount for understanding 
receptor-ligand interactions and can provide key information for the design of effective 
glycomimetic drugs.  
The degree of flexibility of saccharides depends to a greater extent on the free rotation 
around the inter-glycosidic bonds. In the case of the (16) disaccharide shown in figure 
2.1, the relative orientation of the two monosaccharides is described by the torsion angles 
 (H1-C1-O-C6’),  (C1-O-C6’-C5’), and  (O-C6’-C5’-H5’). Equivalent definitions are used 




Figure 2.1. Torsional angles in (16) disaccharides 
The conformation of the rings depends on the spatial distribution of the substituents. In 
sugars, two chair conformations are possible and the chair displaying a higher number of 
equatorial groups is typically preferred. In the case of natural saccharides made of 
common pyranoses (glucose, mannose, galactose, glucosamine, etc.) the predominant 
conformation of the ring is designated as 4C1 chair conformation.  
 
Figure 2.2. Chair conformations of pyranose rings 
Given the possibility to rotate around three consecutives  bonds, pyranose saccharides 
with (16) linkages are usually more flexible compared with saccharides connected via 
(11), (12), (13), and (14) linkages. The conformation around C5-C6 () can exist 
in three staggered conformations denoted gauche-gauche (gg), gauche-trans (gt), and 
trans-gauche (tg) and the contribution of each rotamer to the equilibrium is influenced 
by the configuration of the stereocenter C4, the nature of the substituents on C4 and C6, 
the polarity of the solvent, the configuration of the anomeric carbon, and the nature of 




Figure 2.3. Staggered conformations around C5-C6 bonds  
Previous studies on protected O-, S- and C-glucosides showed that, in organic media, the 
rotamers with major contributions to the conformational equilibrium are gg and gt and 
this equilibrium can progressively be displaced to a greater gt population by increasing 
the bulkiness of the aglycone substituent. In fact, Vazquez et. al showed that exists a 
linear correlation between the percent contribution of gt with the Taft’s steric parameter 
of the aglycone substituent (figure 2.4). 56-58  
 
Figure 2.4. Relationship of the percent contributions of gg and gt rotamers with the steric 






Figure 2.5. Summary of the influence of the steric properties of the aglycone on the 
conformational equilibrium around C5-C6 
 
The remote conformational control described above can be observed in ether- and ester-
protected glucosides, mannosides, and galactosides. The polarity of the media also has 
an influence over the rotamer populations by changing the slope of the trends.  
A different behavior is observed in the case of unprotected glycosides where there is not 
an observable influence of C1 substituents over the hydroxymethyl (C5-C6) conformation. 
Plausible explanations of this finding can be a more significant influence of the solvent 
polarity and the possibility of free hydroxyls to make intramolecular hydrogen bonds 
adding rigidity to the system. 
The study of how the steric properties of the aglycone affects the rotational equilibrium 
around the C5-C6 bond have extensively been performed in protected monosaccharides 
as well as in protected glycosides of gentiobiose (Glc(16)GlcOR). To the best of our 
knowledge, this type of studies has not been extended to other classes of saccharides 
neither unprotected glycosides. 
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In order to explore the presence of this effect in complex saccharides and deepen our 
understanding about their conformational properties, we centered our attention in 
rutinose, a disaccharide made of L-rhamnose and D-glucose, as a model compound for 
carrying out the conformational studies. Rutinose contains the linkage of interest (16) 
and includes a relatively hydrophobic 6-O substituent, rhamnose, that might contribute 
to diminish the conformational control exercised by polar protic solvents such as water. 
We foresee that the conformational study of unprotected -O-rutinosides will reveal 
clues about to what extent the nature of the aglycone can modulate the conformational 
properties of saccharides. The results from this study may provide valuable tools for the 
design of conformational glycomimetics in a near future. The study can also be useful and 
can be applied for conformational analysis of Gal Glycomimetics. 
 
Figure 2.6. Structure of rutinose (L-Rha(16)-D-Glc) and general structure of the -rutinosides 





The synthesis of the target -O-rutinosides 14(a-d) started with the preparation of the L-
rhamnose donor 4 and the D-glucose acceptor 10. 
The rhamnose trichloro-acetimidate donor 4 was prepared in three steps from 
commercially available L-rhamnose 1. Treatment of 1 with Ac2O in pyridine afforded the 
respective per-acetylated donor 2 which was then subjected to the regioselective removal 
of the anomeric acetate by treatment with NH2NH2 and AcOH in DMF. The resulting 
anomeric alcohol 3 was reacted with Cl3CCN and DBU in DCM for generating the target 
rhamnose donor 4 in 78% overall yield. 
 
Scheme 2.1. Synthesis of L-rhamnose donor 4. a) Ac2O, Py, CH2Cl2, rt. 60 mins, b) NH2NH2, HOAc, 
DMF, rt. 24h, c) Cl3CCN, DBU, DCM, rt. 12h.  
 
The preparation of the glucose-derived acceptor 10 (scheme 2.2) started from -penta-
O-acetyl glucose. The glycosylation reaction of benzyl alcohol with the acetate donor 5 
was performed in MeCN using BF3Et2O as catalyst and the desired glycoside 6 was isolated 
in 75% yield. The removal of the acetyl protecting groups of 6 was achieved in quantitative 
yield by treatment with NaOMe in MeOH. The regioselective protection of the hydroxyl 
group on C6 was accomplished by making the respective trityl-protected glycoside 8 
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derived from the reaction of 7 with (Ph)3CCl in pyridine. The free hydroxyl groups on C2, 
C3 and C4 in 8 were then protected as benzoyl esters by BzCl/pyridine treatment. This 
procedure afforded the fully protected intermediate 9 in 60% yield. The final removal of 
the trityl group on C6, performed by dissolving 9 in neat TFA, yielded the target acceptor 
10 in quantitative yield. 
 
Scheme 2.2. Synthesis of glucose acceptor 10. a) BnOH, BF3Et2O, MeCN, b) NaOMe, MeOH, c) 
(Ph)3CCl, Py, 2hrs d) BzCl, Py, 8hrs e) TFA/DCM 
 
The activation of 4 with TMSOTf in the presence of the acceptor 10, lead to the 
stereoselective formation of the desired-(16) linkage with the glucose moiety. The 
anchimeric participation of the axial acetyl group over C2 in the rhamnose ring accounts 
responsible for the selective formation of the 1,2-trans linkage and formation of the -
(16) stereoisomer was not observed. Thus, the assembly of the O-benzyl rutinoside 11 






Scheme 2.3. Assembly of rutinose glycoside 11. a) TMSOTf, DCM, 0oC, 20 min. 
The 13C NMR spectra of 11 shows two anomeric carbons at 99.2 ppm and 98.3 ppm and 
the anomeric protons were identified by their respective cross peaks with C1 in the HSQC 
spectra. The two anomeric protons appear, as expected, as doublets in the 1H NMR 
spectra at 4.94 ppm and 4.82 ppm with 3JH1-H2 coupling constants of < 1.0 Hz and 7.9 Hz 
respectively. The signal with the large J value (7.9 Hz) is assigned to the -glucose ring 
since coupling constants between 7 and 10 Hz can only be generated by trans-diaxial 
systems with dihedral angles close to 180o, a configuration that, in the case of rutinose, 
only the -glucose can fulfil given the axial disposition of both H1 and H2. The situation 
for rhamnose is different and the 3JH1-H2 coupling constants in both  and  anomers are 
predicted to vary from 1 to 4 Hz, given that the dihedral angles for both  and  isomers 
are close to 60o which is associated with small J values according to Karplus equations.59, 
60 Therefore, the analysis of 3JH1-H2 is an ambiguous criterion for assigning the anomeric 
configuration in rhamnosides and the confirmation of the configuration of the Rha-
(16)-Glc glycosidic linkage must be done by an alternative method such as the analysis 
of spatial couplings of H1. Alternatively, it is safe to assume that the major compound is 
expected to be the  adduct considering the structure of the glycosyl donor that includes 




Figure 2.7. HSQC spectra of benzyl-O-rutinoside 11.  
In pyranose rings, the axial hydrogens appear, in general, more de-shielded versus 
equatorial protons. From the comparison of the anomeric hydrogens of glucose (4.82 
ppm) and rhamnose (4.94 ppm) we can speculate that the rhamnose H1 could be 
occupying an axial position. In the same approach, the 13C NMR spectra show the 
anomeric carbon assigned to rhamnose (98.3 pm) more shielded compared with the C1 
of glucose (99.2 ppm). This analysis provides additional information for assigning the 
anomeric configuration of the rhamnose moiety since, normally, -anomeric carbons are 
more shielded than .  
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To study the conformational properties of rutinose glycosides and determine to what 
extent the nature of the alcohol substituents controls it, we propose the synthesis of a 
series of rutinose glycosides of aliphatic alcohols with representative steric properties. 
Benzyl rutinose glycoside 11 was envisaged as a key intermediate for preparing, on a 
multigram scale, the convenient rutinose trichloro-acetimidate donor 13. Palladium-
catalyzed hydrogenolysis of the anomeric benzyl group in 11 lead to the quantitative 
formation of the anomeric alcohol 12 which was immediately converted into the 
trichloro-acetimidate donor 13 by treatment with Cl3CCN and DBU in DCM. The rutinose 
donor 13 was obtained in 81% overall yield from 11.  
 
Scheme 2.4. Synthesis of rutinose imidate 13 and generation of aliphatic rutinose glycosides 14a-
14d. a) H2, Pd/C, EtOH, rt, 48h. b) Cl3CCN, DBU, CH2Cl2, rt, 12h. c) R-OH, TMSOTf, MeCN, 0oC to rt. 
30 min.  
 
Rutinose glycosides 14(a-c) were prepared by glycosylation of the respective aliphatic 
alcohols with donor 13. The reactions were carried out in MeCN and the donor was 
activated with a catalytic amount of TMSOTf. MeCN was selected as a solvent because of 
its effect in favoring the formation of equatorial adducts which, combined with the 
presence of a participating group on C2 in 13, lead to the formation of -glycosides as 
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major products. This procedure afforded the desired glycosides 14(a-c) in excellent yields 
(85-99%). 
The NMR characterization of the products was carried out in CDCl3 at 25oC and selected 
1H and 13C NMR data for rutinosides 11 and 14(a-c) is summarized in table 2.1. From the 
analysis of the data for aliphatic rutinose glycosides 14(a-c), a trend on 1H chemical shifts 
for the glucose anomeric proton can be observed where H1 moves to lower field as the 
degree of substitution of the aglycone increases. Similar behavior is observed for C1 of 
glucose. In the case of rhamnose both anomeric proton and carbon remains practically 
invariable along the series. 
Table 2.1. Selected NMR (CDCl3, 300 MHz) data for rutinosides 14(a-c) 
  
 
Compound R H1 H1’ H5 H5’ H6R H6S C1 C1’ 
11 Benzyl 4.94 4.83 4.01 3.86 -* - 99.2 98.3 
14a Methyl 4.65 4.78 3.95 3.76 -* - 101.9 98.2 
14b iso-Propyl 4.87 4.89 4.03 3.99 - - 99.9 98.2 
14c Cyclohexyl 4.88 4.86 4.01 3.81 - - 99.6 98.2 
* ““ = overlapped signal, no chemical shifts can be read from spectra 
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The values of 3JH5-H6R and 3JH5-H6S were extracted from the splitting pattern of H5 since a 
direct measurement from H6pro-R and H6pro-S was not possible due to the overlapping of 
both signals. Fortunately, H5 appeared well isolated and allowed the reading of 3JH5-H6R 
and 3JH5-H6S in the four rutinosides presented. Table 2.2 shows the measured values of 3JH5-
H6R and 3JH5-H6S for compounds 14(a-c) and their respective calculated populations for the 
rotamers gg, gt, and tg.  
Table 2.2. 3JH5-H6R and 3JH5-H6S values (CDCl3, 300 MHz, 21oC) for rutinosides 14(a-c). 
  3JH5-H6S 3JH5-H6R Pgg Pgt Ptg 
11 Benzyl 4.0 5.5 34 37 29 
14a Methyl 2.6 7.0 37 61 2 
14b iso-Propyl 4.2 5.6 39 41 20 
14c Cyclohexyl 5.0 5.0 39 32 29 
                                                                                      *Pgg, Pgt, Ptg in Percentage (%) 
The percent contribution of each rotamer to the conformational equilibrium was 
calculated from the 3JH5-H6R and 3JH5-H6S values using Karplus-like equations. Several 
equation systems are available for calculating rotamer populations about C5-C6.59, 61-65 
We opted for the system proposed by Serianni66 in 2004 since this system has been 
demonstrated to provide accurate results in addition to positive values for the tg rotamer 




2.8 Pgg + 2.2 Pgt + 11.1 Ptg = 3JH5H6S 
0.9 Pgg + 10.8 Pgt + 4.2 Ptg = 3JH5H6R 
Pgg + Pgt + Ptg = 1 
Equations 2.1. Serianni’s equations used in this work for calculation rotational populations in 
rutinose glycosides 
 
The analysis of the calculated populations for rutinosides 14(a-c) and 11 shows the three 
rotamers, gg, gt, and tg contributing to the equilibrium and the percent contribution of 
the gg rotamer exhibits minor variations along the series remaining practically constant. 
However, populations of gt and tg exhibit significant variation through the series. In 
particular, the contribution of tg increases at gt expense as the bulkiness of the aglycone 
increases. In compound 14a, the rutinose glycoside substituted with the smallest alkyl 
group (methyl), the conformational equilibria about C5-C6 is predominated by the gt 
rotamer with a contribution of 61%, followed by gg with 37%, and tg with 2%. For 
cyclohexyl glycoside 14c, substituted with the bulkiest group of the series, the 
conformation is predominated by the gg rotamer with 39% contribution, followed by gt 
and tg with 32% and 29% respectively. The influence of the steric properties of the 
aglycone over the conformation about C5-C6 is more evident when comparing the Pgt 
and Ptg differences between 14a and 14c, being Pgt and Ptg 29% and 27% respectively. 
These results are consistent with reported data regarding the remote conformational 
influence of the aglycone over the  torsion.67 
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The figures 2.10 and 2.11 show the relationship between the calculated rotamer 
populations and the Taft steric parameter (ES), a molecular descriptor of the steric 
properties of alkyl groups. In figure 2.10 the calculated gt, gg, and tg populations of 
aliphatic rutinose glycosides 14(a-c) are represented as a function of ES. The data shows 
a clear linear relationship between the contributions of gt and tg rotamers with ES. In 
particular, the percent contribution of the tg rotamer increases, at the cost of the gt 
contribution, as ES of the aglycone substituent is more negative. In other words, the 
rotamer equilibrium is progressively displaced towards tg predominance as the bulkiness 
of the aglycone increase. The percent population of the gg rotamer does not vary as a 
function of ES and remains constant along the series.  
 
 
Figure 2.8. Relationship between gg, gt and tg rotamer populations with Taft’s steric parameter 




The variations of tg and gt populations among the glycosides studied provide evidence of 
a remote conformational control exerted by the substituent group of the aglycone where 
the conformational equilibrium around C5-C6, an inter-glycosidic linkage in our model 
compounds, can be influenced by groups attached at a three bond distance. The linear 
dependency of Pgt and Ptg with ES provides an insight about the significance of the steric 
properties of the aglycone substituent on this effect. However, steric properties cannot 
be regarded as the only variable exerting the observed conformational control and other 
factors, such as electronic and polar attributes, should also be considered. This becomes 
evident when including the rutinose glycoside of benzyl alcohol 11, with non-aliphatic 
aglycone substituent, in the representation of the rotamer populations versus ES (figure 
2.11). The inclusion of 11 in the series leads to a loss of linearity indicating that electronic 
factors also play a role in the modulation of the conformational properties of rutinose 
glycosides. 
The conformational behavior of the studied rutinosides differ from the behavior observed 
for other types of glucose-derived saccharides. In the case of per-acetylated O-
glucosides,68 O-mannosides,69 and S-gentiobiosides (Glc(16)GlcSR)70 the 
conformation about C5-C6 is also influenced by the steric properties of the aglycone being 
gt the rotamer that increases its contribution, at the expense of gg, as the bulkiness of 
the aglycone increase. In addition, the contribution of tg in these classes of glycosides is 




Figure 2.9. Relationship between gg, gt and tg rotamer populations with Taft’s steric parameter 
of the aglycone substituent.  
 
the atypical high tg population observed in rutinosides 11 and 14(a-c) could be the 
stabilizing effect of the CH- interaction between the methyl group of rhamnose (C-6’) 
and the aromatic ring of the benzoyl group on C-4 of glucose (figure 2.12.). Using methyl 
O-rutinoside 14a as a model, the optimized structure (MMFF94) of its tg conformer shows 
a 3.6 Å distance between the C-6’ hydrogen and the center of the C-4 benzoyl ring, a value 




Figure 2.10. Proposed stabilization of the tg rotamer via CH- interaction between the methyl 
group C-6’ of rhamnose and the aromatic ring of the benzoyl group over C-4 of glucose. 
 
Although there is not a conclusive explanation for the dependency of Pgg, Pgt and Ptg 
with the aglycone’s ES, a hypothesis based on stereoelectronic effects seems plausible. In 
carbohydrate chemistry it is postulated that the preference of electronegative C1 
substituents for the axial position (anomers) can be explained based on the combined 
stabilization of two stereoelectronic interactions between a lone electron pair of the 
electronegative heteroatom X (nX) with the sigma antibonding orbital of the C1-O5 bond 
(*C1-O5) and the interaction of the axial lone electron pair of O5 (nO5) with the sigma 
antibonding orbital of the C1-X bond (*C1-X). These interactions are named the exo-
anomeric and the endo-anomeric effects, respectively. In the case of -glycosides, the 
geometry of the anomeric carbon fulfills the requirements for the exo-anomeric effect to 
take place whereas both exo- and endo-anomeric effects are possible in the -glycosides 




Figure 2.11. Stereoelectronic interactions  
A consequence of hyperconjugation interactions is the shortening of the bond where the 
donor atom is connected and the subsequent enlargement of the bond that holds the 
antibonding orbital. In the case of -glycosides, the C1-O5 bond is longer because of the 
C1-O(R) bond shortening. We hypothesize that the variations in the bond lengths may 
have an effect in de-stabilizing the gg rotamer resulting in a displacement of the 
equilibrium towards a higher contribution of gt and/or tg as a result of the geometrical 
change in the molecular neighborhood. Stereoelectronic interactions also can be 
proposed in the stabilization of the gg and gt conformers. The donation of the C5-H5 
sigma bond to the C6-O6 sigma antibonding orbital (C5-H5*C6-O6) can stabilize gg 
rotamer whereas the interaction C6-H6S/C5-O5 (C6-H6S*C5-O5) can stabilize gt. A 
similar analysis for tg involves the donation of the C6-H6R to C4-C5 (C6-H6R*C4-C5), 
however, this type of interaction is less likely to take place given the poor acceptor 
character of the C-C bonds. Hence, the results observed for the rutinosides studied herein, 
i.e. an increment of tg population along the series, cannot be explained based on the C6-
H6R*C4-C5 interaction and the stabilization by CH- interaction seems more reasonable. 
On the other hand, the general tendency of the rotational populations to linearly change 
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with respect to the steric properties of the aglycone is a phenomenon that remains to be 
explained.  
 





3. Future work 
The aim of this work is to determine the conformational properties of fully deprotected 
saccharides in solution and we have chosen rutinose glycosides as model compounds for 
carrying out this study. The data obtained from the conformational analysis of protected 
rutinosides 14(a-c) showed an unexpected behavior for this class of compounds and 
further studies will be carried out on homogeneously protected derivatives (i.e. per-
acetylated compounds) for a direct comparison with previous data and test the 
hypothesis of tg stabilization via CH- interaction. We consider including other types of 
saccharides into this study depending on the results observed for the per-acetylated 
series.  
 
Scheme 2.5. Synthesis of rutinose glycoside 14e and 14f. a) R-OH, TMSOTf, MeCN, 0oC to rt. 30 
min.  
The studies of the deprotected model compounds will be carried out after completing the 
synthesis of two remaining compounds, substituted with ethyl and tert-butyl O-
aglycones, for increasing the number of collected data points and making the analysis 








4. Experimental Section 
 
1,2,3,4-tetra-O-acetyl L-rhamnose (2): Rhamnose 1 (5g, 3.45 mmol) 
was dissolved in pyridine (11.05 mL) and cooled to 0°C. Acetic 
anhydride (25.8mL, 273.15 mmol) was then added was added to the solution and the 
solution was allowed warming to r.t. After 2 hours of stirring TLC analysis shows total 
consumption of the starting material and the volatiles were removed in vacuo. Acetylated 
product was then purified by flash silica gel chromatography using EtOAc/Hexanes 
mixture (1:1) as eluents. Compound 2 (1.68 g,  2.97 mmol 99%, Rf 0.7) was isolated as a 
white solid. Compound identity was confirmed by comparison of 1H and 13C NMR spectra 
with previously reported data.74 
2,3,4-tri-O-acetyl L-rhamnose (3): A solution of (90.9 g, 274 mmol) of 
peracylated sugar 2 in of tetrahydrofuran (150 mL) was added to an 
ammonical solution of (1500 mL) of tetrahydrofuran-methanol (2.3:1, prepared by 
bubbling ammonia into the solvent for 30 min) cooled in an ice-water bath.  The cooling 
bath was removed, and the solution warmed to rt.  After 5.5 h, thin layer chromatography 
(silica gel; dichloromethane-methanol, 9:1) showed consumption of 2, and the solvent 
removed in vacuo.  The residue was triturated with approximately 150 mL of diethyl ether 




O-(2-trichloroethanimine)-2,3,4-tri-O-acetyl L-rhamnose (4): 
Rhamnose-1-OH 3 is dissolved in DCM. Trichloroacetonitrile is 
then added to the solution with stirring. DBU is then added and the solution is allowed to 
stir at room temperature for 12 hrs. After 12 hrs TLC analysis shows complete conversion 
to product. Volatiles are removed in vacuo. The crude so obtained is purified by flash 
chromatography using SiO2 as stationary phase and EtOAc/Hexanes mixture (3:7) as 
eluent. glycoside 4 (7.55 g, 17.2 mmol, 75.15%) was isolated as a waxy white solid. 
Compound identity was confirmed by comparison of 1H and 13C NMR spectra data. 75 
O-benzyl-2,3,4,6-tetra-O-acetylglucoside (6): Glucose 
pentaacetate 5 (10.07 g, 25.7 mmol) and Benzyl alcohol ( 5.34 ml, 
51.4 mmol) were dissolved in dry Acetonitrile (77.1 mL) and BF3Et2O (1.58 mL, 12.85 
mmol) was added dropwise and the solution was refluxed at 50 – 800C under stirring. 
After 6 hours of TLC shows total consumption of the starting material and the reaction 
was cooled to 0oC and quenched with triethylamine (4.0 mL). After 15 minutes of stirring 
at 0oC, the volatiles were removed in vacuum and the crude purified by flash 
chromatography using SiO2 as stationary phase and EtOAc/Hexanes mixture (3:7) as 
eluent. O-benzylglycoside 6 (7.55 g, 17.2 mmol, 75.15%) was isolated as a waxy white 
solid. Compound identity was confirmed by comparison of 1H and 13C NMR spectra data 
with previously reported data. 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.26 (m, Aromatic H’s, 
6H), 5.09 (dd, J = 9.3 Hz and 6.06 Hz, H-4), 5.03 (dd, J = 8.5 Hz and 9.5 Hz, H-3), 4.99 (dd, J 
= 9.3 Hz and 7.7 Hz, H-2), 4.82 (d, J = 12.3 Hz, 1H), 4.56 (d, J = 12.3 Hz, 1H), 4.48 (d, J = 7.9 
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Hz, H-1), 4.21 (dd, J = 12.3, 4.7 Hz, H-6), 4.10 (dd, J = 12.3, 2.4 Hz, H-6’), 3.60 (ddd, J = 9.6, 
4.6, 2.4 Hz, H-5), 2.04 (s, 3H), 1.95 (s, 3H), 1.94 (s, 3H), 1.93 (s, 3H). 13C NMR (100 MHz, 
CDCl3) δ 170.7, 170.3, 169.4, 169.3, 140.9, 136.6, 128.6, 128.5, 128.1, 127.8, 127.7, 127.0, 
99.3, 77.3, 77.0, 76.7, 72.8, 71.9, 71.3, 70.8, 68.4, 65.4, 61.9, 20.8, 20.6, 1.0.51 
O-benzylglucoside (7): O-benzyl-2,3,4,6-tetra-O-acetylglucoside 6 
(7.24 g, 15.9 mmol) was dissolved in methanol (30.0 mL) and sodium 
methoxide (100 mg) was added. The suspension was stirred at r.t. for 24 hours which is 
enough time for the trans-esterification reaction to be completed (shown by TLC analysis). 
The system was then neutralized with Amberlyst IR-120+ resin followed by filtration. 
Methanol was removed in vacuo with rotary evaporator and the crude dried under high 
vacuum in a Schlenk line for 24 hours prior to use. Structure of 1-benzyloxy-ß-D-
glucopyranoside 7 was confirmed by comparison of its 1H and 13C NMR spectra with 
previously reported data. 1H NMR (400 MHz, CDCl3) δ 7.32 – 7.18 (m, Aromatic H’s, 5H), 
4.75 (d, J = 12.0 Hz, 1H), 4.49 (d, J = 11.4 Hz, 1H), 4.29 (d, J = 5.6 Hz, 1H), 3.71 (s, 2H), 3.51 
(s, 1H), 3.35 (s, 2H), 3.13 (s, 1H). 13C NMR (100 MHz, CDCl3) δ 136.1, 127.4, 127.1, 76.3, 
76.2, 75.9, 75.7, 70.3, 59.4, 20.0, 13.2.51 
 O-benzyl-6-O-(triphenylmethyl)glucoside (8) O-benzylglucoside 7 
(3.65g, 13.5 mmol) was dissolved in Pyridine (21 ml) and Triphenyl 
chloride (3.76 g, 13.5 mmol) was added to the solution. The solution was heated at 700C  
and stirred for 2 hours. After 2 hours of stirring TLC analysis shows total consumption of 
the starting material. The reaction was then diluted with distilled water and with water 
and ethyl acetate. The volatiles were then removed in vacuo. 2,3,4-Diol 9 was then 
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purified by flash silica gel chromatography using EtOAc/Hexanes mixture (2:3) as eluents. 
Compound 8 (3.5 g,  6.82 mmol 60%) was isolated as a  yellowish white solid. Compound 
identity was confirmed by comparison of 1H and 13C NMR spectra with previously 
reported data.76 
O-benzyl-2,3,4-tribenzoyl-6-O-(triphenylmethyl)glucoside (9): O-
benzyl-6-O-(triphenylmethyl)glucoside 8 (6.83 g, 3.5 mmol) was 
dissolved in pyridine (5.25 mL) and benzoyl chloride (2.9 mL, 24.58 mmol) was added to 
the solution at r.t. After 3 hours of stirring TLC analysis shows total consumption of the 
starting material and the volatiles were removed in vacuo. Tribenzoylated adduct was 
then purified by flash silica gel chromatography using EtOAc/Hexanes mixture (2:3) as 
eluents. Compound 9 (1.68 g, 2.97 mmol 99%) was isolated as a  yellowish white solid. 
Compound identity was confirmed by comparison of 1H and 13C NMR spectra with 
previously reported data. 1H NMR (400 MHz, CDCl3) δ 7.92 – 7.10 (m, Aromatic H’s, 35H), 
5.72 (dd, J = 9.4 and 9.4 Hz, H-3), 5.61 (d, J = 7.9 and 7.9 Hz, H-2), 5.59 (d, J = 9.4 and 9.4 
Hz, H-4), 4.99 (d, J = 11.9 Hz, 1H), 4.81 (d, J = 11.9 Hz, 1H), 4.78 (d, J = 8.7 Hz, H-1), 3.80 
(m, H-5), 3.32 (m, 2H, H-6 and H-6’). 13C NMR (100 MHz, CDCl3) δ 130.8, 129.7, 129.1, 
128.6, 128.4, 127.7, 126.9, 77.3, 77.2, 77.0, 76.7, 30.9. 
 O-benzyl-2,3,4-tribenzoylglucoside (10): O-benzyl-2,3,4-
tribenzoyl-6-O-(triphenylmethyl)glucoside 9 ( 1.3g, 1.57 mmol) was 
dissolved in a mixture of TFA/DCM (2:8, 10.0 mL) at r.t. and stirred for 30 minutes. After 
that period TLC analysis shows complete consumption of the starting material. Then TFA 
and water were removed in vacuo with rotary evaporator and the crude diol was purified 
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by flash chromatography with silica gel as stationary phase and EtOAc/Hex mixtures (1:1) 
as eluents. Compound 10 (8.70 g, 17.6 mmol, 92%) was isolated as a white solid. 1H NMR 
(400 MHz, CDCl3) δ 7.92 (d, J = 7.7 Hz, 4H), 7.83 (d, J = 7.6 Hz, 2H), 7.54 (m, 2H), 7.46 – 
7.38 (m, 5H), 7.30-7.20 (m, 7H), 5.88 (dd, J = 9.8, 9.8 Hz, H-4), 5.58 (dd, J = 7.9 and 9.5 Hz, 
H-2), 5.49 58 (dd, J = 9.3 and 9.3 Hz, H-3), 4.92 (d, J = 12.6 Hz, 1H, OCH2 Ph), 4.84 (d, J = 
8.0 Hz, H1), 4.74 (d, J = 12.7 Hz, 1H, OCH2 Ph), 3.87 (dd, J = 4.2 and 14.3 Hz, H6), 3.74 (m, 
H5, H6’). 13C NMR (100 MHz, CDCl3) δ 207.0, 166.1, 165.8, 165.1, 136.7, 133.7, 133.2, 
129.9, 129.8, 129.7, 129.3, 128.8, 128.5, 128.4, 128.3, 127.9, 127.8, 99.5, 77.3, 77.2, 77.0, 
76.7, 74.6, 72.7, 71.8, 70.9, 69.6, 61.4, 30.9.77 
2,3,4-tetra-O-acetyl-L-rhamnose-1→6-O-benzyl-2,3, 
4-tribenzoylglucoside (11): Monosaccharide 4 (9.1 
mg, 0.0162 mmol) and Alcohol 10 (9.7 mg, 3.3 mmol) were dissolved in DCM (65.12 L) 
in the presence of 4A0 molecular sieves (1.0 mg). The suspension was stirred at r.t. for 15 
mins and then cooled to -20 - 30oC using dry ice. TMSOTf (0.3 L, 0.0016 mmol) was then 
added and vigorous stirring was continued until total consumption of the donor was 
observed (TLC 2 hours). Reaction was then diluted with ethyl acetate (5.0 mL), quenched 
with Et3N (0.5 mL), allowed to warm to r.t., filtered over a Celite® bed, transferred to a 
separation funnel and washed with NaS2O3. The organic fraction was dried over Na2SO4, 
the volatiles removed in vacuo and the crude purified by flash chromatography using silica 
gel as stationary phase and EtOAc/Hexanes (1:2) gradient as eluent solutions. 
Glycosylated monosaccharide 32 (8.2 mg, 0.011 mmol, 90 % ) was isolated as a yellow 
solid. 1H NMR (400 MHz, CDCl3) δ 7.94 – 7.19 (m, Aromatic H’s, 20H), 5.83 (dd, J = 9.6 and 
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9.6Hz, H-3), 5.57 (dd, J = 8.1 and 9.7 Hz, H-2), 5.44 (dd, J = 9.7 and 9.7 Hz, H-4), 5.38-5.36 
(m, 1H), 5.30 (dd, J = 10.0, 3.4 Hz, H-4’), 5.08 (dd, J = 9.9  and 9.9 Hz, H-5’), 4.93 (dd, J = 
4.6 and 7.8 Hz, H-1’, H-3’), 4.82 (d, J = 7.9 Hz, H-1), 4.73 (d, J = 12.7 Hz, H-2’), 4.03 – 3.98 
(m, H-5), 3.90 – 3.80 (m, 2H, H6R, H6S), 2.14 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 1.16 (d, J = 
6.2 Hz, 3H, H-6’). 13C NMR (101 MHz, CDCl3) δ 170.0, 165.7, 165.3, 165.1, 136.6, 133.5, 
133.2, 129.9, 129.8, 129.7, 128.5, 128.4, 128.3, 128.3, 127.9, 99.2, 98.3, 77.4, 77.0, 76.7, 
70.5, 66.9, 20.9, 20.8, 20.7, 17.3, 14.2, 12.9. 
2,3,4-tetra-O-acetyl-L-rhamnose-1→6-2,3,4-tribenzo 
ylglucoside (12): Disaccharide 11  is first dissolved in 
was ethanol. Weighed quantity of the catalyst is added to the flask. Flask is evacuated and 
backfilled with nitrogen gas 3 times. The flask is then evacuated and backfilled  with 
hydrogen gas. Hydrogen balloons are then attached to the flask and the reaction can run 
at r.t. for 24 hrs. After 24 hrs TLC analysis shows complete consumption of substrate. 
When the reaction is done, the contents of flask are poured into a filter funnel containing 
celite to remove the palladium catalyst. Volatiles are than removed in vacuo. Compound 
12 is isolated as white solid. The crude is then directly used to set up next reaction without 




2,3,4-tribenzo ylglucoside 12 is dissolved in DCM. Trichloroacetonitrile is then added to 
the solution with stirring. DBU is then added and the solution is allowed to stir at room 
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temperature for 12 hrs. After 12 hrs TLC analysis shows complete conversion to product. 
Volatiles are removed in vacuo. The crude so obtained is purified by flash chromatography 
using SiO2 as stationary phase and EtOAc/Hexanes mixture (3:7) as eluent. glycoside 4 
(7.55 g, 17.2 mmol, 75.15%) was isolated as a waxy white solid. Compound identity was 
confirmed by comparison of 1H and 13C NMR spectra data. 1H NMR (400 MHz, CDCl3) δ 
7.99 – 7.30 (m, 17H), 6.76 (d, J = 3.7 Hz, H1), 6.24 (t, J = 9.9 Hz, H3), 5.62 (t, J = 10.1 Hz, 
H2), 5.57 (dd, J = 10.2, 3.7 Hz, H4), 5.28 (m, H2’), 5.23 (dd, J = 10.0, 3.5 Hz, H3’), 5.02 (t, J 
= 9.9 Hz, H4’), 4.83 (d, H-1’), 4.50 – 4.44 (m, H5), 3.87 (m, H6R), 3.82 (m, H5’), 3.73 (dd, J 
= 11.8, 6.1 Hz, H6S), 2.14 (s, 3H), 2.04 (s, 3H), 1.97 (s, 3H), 1.15 (d, J = 6.2 Hz, 3H, H6’). 13C 
NMR (100 MHz, CDCl3) δ 206.9, 129.9, 129.7, 128.5, 128.4, 128.3, 98.0, 93.8, 92.9, 77.3, 
77.0, 76.7, 71.1, 70.6, 70.2, 69.5, 68.9, 66.6, 30.9, 20.8, 20.7, 17.3. 
2,3,4-tetra-O-acetyl-L-rhamnose-1→6-O-methyl-2,3, 
4-tribenzoylglucoside (14a): Disaccharide 13 (885 mg, 
1.65 mmol) and Dry Methanol (0.988 g, 3.3 mmol) were dissolved in Acetonitrile (6.6 mL). 
The solution was then cooled to 0oC . TMSOTf (29.8 L, 0.165 mmol) was then added and 
vigorous stirring was continued until total consumption of the donor was observed (TLC, 
30 mins). The volatiles removed in vacuo and the crude purified by flash chromatography 
using silica gel as stationary phase and EtOAc/Hexanes (1:2) gradient as eluent solutions. 
Glycosylated disaccharide 14a ( 787.3 mg, 1.08 mmol,88.93% ) was isolated as a white 
solid. 1H NMR (400 MHz, CDCl3) δ 7.89 – 7.20 (m, 15H), 5.80 (t, J = 9.7, 9.7 Hz, H3), 5.40 
(dd, J = 9.7, 8.0 Hz, H2), 5.33 (d, J = 9.7 Hz, H4), 5.20 (m, H3’), 5.17 (d, J = 3.5 Hz, H2’), 4.97 
(dd, J = 17.3, 7.5 Hz, H4’), 4.79 (s, H1’), 4.65 (d, J = 7.9 Hz, H1), 4.00 – 3.91 (m, H5), 3.82 – 
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3.76 (m, H5’,H6R), 3.76 – 3.66 (m, H6S), 2.06 (s, 3H), 1.99 – 1.93 (m, 3H), 1.91 (s, 3H), 1.17 
(dd, J = 16.5, 7.6 Hz, OCH3), 1.06 (d, J = 6.2 Hz, H6’). 13C NMR (100 MHz, CDCl3) δ 169.9, 
169.9, 165.8, 165.3, 165.1, 133.5, 133.2, 129.8, 129.7, 129.3, 128.8, 128.7, 128.5, 128.4, 
128.3, 101.9, 98.3, 77.3, 77.0, 76.7, 74.2, 72.9, 71.8, 71.0, 69.9, 69.6, 69.0, 67.1, 66.5, 57.2, 
53.4, 29.7, 20.9, 20.8, 20.7, 17.3. 
2,3,4-tetra-O-acetyl-L-rhamnose-1→6-O-isopropyl 
-2,3,4-tribenzoylglucoside (14b): Disaccharide 13 
(885 mg, 1.65 mmol) and dry Methanol (0.988 g, 3.3 mmol) were dissolved in Acetonitrile 
(6.6 mL). The solution was then cooled to 0oC . TMSOTf (29.8 L, 0.165 mmol) was then 
added and vigorous stirring was continued until total consumption of the donor was 
observed (TLC, 30 mins). The volatiles removed in vacuo and the crude purified by flash 
chromatography using silica gel as stationary phase and EtOAc/Hexanes (1:2) gradient as 
eluent solutions. Glycosylated disaccharide 14a (787.3 mg, 1.08 mmol, 88.93%) was 
isolated as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.97 – 7.31 (m, Aromatic H’s, 15H), 
5.88 (dd, J = 9.6 and 9.6 Hz, H3), 5.45 (dd, J = 9.8, 8.3 Hz, H2), 5.41 – 5.36 (m, H4), 5.32 – 
5.29 (m, H2’), 5.26 (dd, J = 10.1, 3.3 Hz, H3’), 5.04 (dd, J = 11.4, 8.2 Hz, H4’), 4.90 (s, H1’), 
4.87 (d, J = 8.06 Hz, H1), 4.04 (dd, J = 9.1, 4.8 Hz, H5), 4.00 – 3.95 (m, H5’), 3.82 – 3.79 (m, 
H6S, H6R), 2.14 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H), 1.22 (d, J = 6.2 Hz, H6’), 1.14 (s, 3H), 1.09 
(d, J = 6.1 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 169.9, 165.8, 133.5, 129.9, 129.8, 129.7, 
128.5, 128.3, 128.2, 99.8, 98.2, 77.3, 77.0, 76.7, 74.2, 73.2, 73.0, 72.0, 71.0, 70.1, 69.5, 





Disaccharide 13 (885 mg, 1.65 mmol) and Dry 
Methanol (0.988 g, 3.3 mmol) were dissolved in Acetonitrile (6.6 mL). The solution was 
then cooled to 0oC . TMSOTf (29.8 L, 0.165 mmol) was then added and vigorous stirring 
was continued until total consumption of the donor was observed (TLC, 30 mins). The 
volatiles removed in vacuo and the crude purified by flash chromatography using silica gel 
as stationary phase and EtOAc/Hexanes (1:2) gradient as eluent solutions. Glycosylated 
disaccharide 14a (787.3 mg, 1.08 mmol,88.93% ) was isolated as a white solid. 1H NMR 
(400 MHz, CDCl3) δ 7.95 - 7.29 (m, 15H), 5.85 (dd, J = 9.7 and 9.7 Hz, H3), 5.48 – 5.42 (m, 
H2), 5.39 (t, J = 9.8 Hz, H4), 5.28 (m, H2’), 5.23 (dd, J = 10.0, 3.4 Hz, H3’), 5.02 (dd, J = 9.9 
and 9.9 Hz, H5’), 4.89 (d, J = 7.9 Hz, H1), 4.86 (s, H1’), 4.04 (m, H5), 3.84 – 3.80 (m, H5’, 
H6R), 3.79 (d, J = 6.4 Hz, H6S), 3.68 (s, 3H), 2.13 (s, 3H), 2.02 (s, 3H), 1.97 (s, 6H), 1.12 (d, 
J = 6.2 Hz, H5’). 13C NMR (100 MHz, CDCl3) δ 169.9, 133.5, 133.1, 133.0, 129.8, 129.7, 
129.7, 128.5, 128.3, 128.2, 99.6, 98.2, 77.3, 77.0, 76.7, 74.1, 73.0, 72.0, 71.0, 70.1, 69.5, 




Figure 2.13. H1 NMR spectra of compound 9 
 




Figure 2.15. H1 NMR spectra of compound 13 
 




Figure 2.17. H1 NMR spectra of compound 14b 
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